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ENGLISH SUMMARY 
BACKGROUND 
Excess mortality in patients with schizophrenia is a well-established fact and the 
subject of widespread and growing concern. The literature indicates that diabetes, 
cardiovascular and respiratory diseases are major contributors to the reduced life 
expectancy of 10-20 year found in this vulnerable population. Yet, there is 
surprisingly sparse data available regarding the quality of care for their medical 
comorbidities. The overall objective of this thesis was therefore to determine the 
association between schizophrenia and the quality and predictors of care for diabetes, 
heart failure and chronic obstructive pulmonary disease (COPD) in Denmark, which 
has a free public health care system. Moreover, the thesis aimed to examine the 
clinical outcomes of heart failure and COPD among patients with schizophrenia. 
These goals were investigated in three nationwide population-based cohort studies. 
 
METHOD 
All three studies were based on individual-level data obtained from national Danish 
registries between 2004 and 2013. The quality of diabetes, heart failure and COPD 
care was defined as meeting guideline-recommended disease-specific process-
performance measures of care in Danish public hospitals. Receiving at least 80% of 
the disease-specific performance measures of care was defined as meeting a high 
quality of care. Potential predictors of care for these medical comorbidities among 
patients with schizophrenia included factors related to patients (sex, age, abuse, 
Global Assessment of Functioning (GAF) score, duration of schizophrenia), to 
providers (quality of schizophrenia care) as well as system-related factors (contact 
volume defined as average contact volume of patients treated for diabetes, incident 
heart failure or COPD per year during the study period in hospital departments and/or 
outpatient clinics). The clinical outcomes of heart failure comprised 4-week all-cause 
readmission and 1-year all-cause mortality following a first-time hospital contact with 
incident heart failure. Clinical outcomes of COPD included 30-day all-cause 
readmission and 30-day all-cause mortality following an admission for exacerbation 
of COPD.  
   
STUDY I 
Study I included 83,813 diabetes hospital outpatients, of which 669 patients also had 
a diagnosis of schizophrenia. Results demonstrated that diabetes patients with 
schizophrenia had a lower chance of receiving 6 out of 11 examined individual 
process-performance measures of diabetes care, including blood pressure monitoring 
((Relative risk) RR 0.98, 95% CI: 0.96-0.99), treatment with antihypertensive drugs 
(RR 0.83, 95% CI: 0.70-0.97) and ACE/ATII inhibitors (RR 0.72, 95% CI: 0.55-0.93), 
screening for albuminuria (RR 0.96, 95% CI: 0.93-0.99), eye examination at least 
every second year (RR 0.97, 95% CI: 0.94-0.99) and foot examination (RR 0.96, 95% 
CI: 0.93-0.99). The meeting of the high quality of diabetes care was also deficient 
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among this group (RR 0.91, 95% CI: 0.88-0.95) compared to diabetes patients without 
schizophrenia. Drug abuse and treatment at outpatient clinics with a low contact 
volume of diabetes patients were associated with an inadequate quality of diabetes 
care among diabetes patients with schizophrenia.  
 
STUDY II 
Study II comprised 36,718 hospital in- and outpatients with incident heart failure, of 
which 108 patients had comorbid schizophrenia. The results showed that patients with 
incident heart failure as well as schizophrenia had a lower chance of receiving 1 out 
of 7 assessed individual process-performance measures of heart failure care, including 
treatment with beta-blockers (RR 0.87, 95% CI: 0.79-0.97). These patients 
furthermore had a lower chance of meeting a high quality of heart failure care (RR 
0.66, 95% CI: 0.48-0.91) than incident heart failure patients without schizophrenia. A 
low GAF score was associated with a deficient quality of heart failure care among 
incident heart failure patients with schizophrenia. Incident heart failure patients with 
schizophrenia had a higher risk of 1-year mortality (adjusted hazard ratio (HR) 2.85, 
95% CI: 1.59-5.09), but not a higher risk of 4-week readmission compared to incident 
heart failure patients without schizophrenia. 
 
STUDY III 
Study III included 72,692 COPD hospital in- and outpatients, of which 621 patients 
also had a diagnosis of schizophrenia. The results showed that COPD patients with 
schizophrenia had a lower chance of receiving 1 out of 9 evaluated individual process-
performance measures of COPD care, comprising treatment with long-acting 
muscarinic antagonists (LAMA) or long-acting β2- agonists (LABA) (RR 0.92, 95% 
CI: 0.87-0.98). This patient population had the same chance of meeting a high quality 
of COPD care (RR 0.95, 95% CI: 0.87-1.03) compared to COPD patients without 
schizophrenia. Male sex was associated with a poor quality of COPD care among 
COPD patients with schizophrenia. COPD patients with schizophrenia had an 
increased risk of 30-day mortality (adjusted odds ratio (OR) 1.27, 95% CI: 1.01-1.59), 
but not a higher risk of 30-day readmission than COPD patients without 
schizophrenia.  
 
CONCLUSION 
Patients with schizophrenia had a lower chance of meeting a number of process-
performance measures for diabetes, heart failure and COPD care, although the 
absolute differences in general were small. The predictors of a poorer quality of care 
included patient- and system-related factors. However, patients with schizophrenia 
had a substantially higher risk of mortality following a first-time hospital contact with 
incident heart failure and after an admission for exacerbation of COPD. Additional 
interventions are therefore warranted to reduce the high mortality rates of heart failure 
and COPD among patients with schizophrenia.  
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DANSK RESUME 
BAGGRUND 
Overdødelighed blandt patienter med skizofreni er et område forbundet med stor 
bekymring. Litteraturen indikerer, at særligt diabetes, hjerte-kar-sygdomme og 
luftvejssygdomme bidrager til en 10-20 års reduceret levetid for denne sårbare 
population. Den eksisterende viden vedrørende kvaliteten af behandlingen for disse 
medicinske følgesygdomme er dog overraskende sparsom. Det overordnede formål 
med denne afhandling var derfor at undersøge associationen mellem skizofreni og 
kvalitet af behandling samt prædiktorer for behandling af diabetes, hjertesvigt og 
kronisk obstruktiv lungesygdom (KOL) i det danske gratis sundhedsvæsen. 
Desforuden sigtede afhandlingen mod at undersøge de kliniske udfald af hjertesvigt 
og KOL blandt patienter med skizofreni. Disse mål blev belyst i tre nationale, 
populationsbaserede kohortestudier.   
METODE 
Alle tre studier blev baseret på individbaserede data indhentet fra nationale danske 
registre mellem 2004 og 2013. Kvaliteten af behandlingen for diabetes, hjertesvigt og 
KOL blev vurderet ud fra, om patienterne modtog de anbefalede sygdomsspecifikke 
procesindikatorer på offentlige danske sygehuse. Såfremt patienterne modtog over 
80% af de anbefalede sygdomsspecifikke indikatorer, blev dette anset som en høj 
behandlingskvalitet. Potentielle prædiktorer for behandling af disse medicinske 
følgesygdomme blandt patienter med skizofreni indbefattede faktorer relateret til 
patienten (køn, alder, misbrug, funktionsniveau vurderet ud fra en GAF-score, 
varighed af skizofreni), til udbyder (kvaliteten af behandlingen for skizofreni) og 
system-relaterede faktorer (kontaktvolumen beregnet på basis af gennemsnittet af det 
årlige antal kontakter med patienter med hhv. diabetes, nydiagnosticeret hjertesvigt 
og KOL på hver enkelt hospitalsafdeling og/eller ambulatorium i studieperioden). De 
kliniske udfald af hjertesvigt omfattede genindlæggelse indenfor 4 uger og mortalitet 
indenfor 1 år efter første hospitalskontakt med nydiagnosticeret hjertesvigt, uanset 
årsag. Derudover indbefattede de kliniske udfald af KOL genindlæggelse indenfor 30 
dage samt mortalitet indenfor 30 dage efter indlæggelse for akut KOL-exacerbation, 
uanset årsag.   
STUDIE I 
Studie I inkluderede 83.813 ambulante diabetespatienter, hvoraf 669 tillige havde en 
diagnose med skizofreni. Resultaterne viste, at diabetespatienter med skizofreni havde 
en lavere risiko for at modtage 6 ud af 11 undersøgte procesindikatorer for diabetes, 
herunder blodtryksmåling (Relativ risiko (RR) 0.98, 95% CI: 0.96-0.99), 
antihypertensiv behandling (RR 0.83, 95% CI: 0.70-0.97) og ACE-hæmmer/ATII-
receptor antagonist (RR 0.72, 95% CI: 0.55-0.93), undersøgelse for albuminuria (RR 
0.72, 95% CI: 0.55-0.93), øjenundersøgelse mindst hvert andet år (RR 0.97, 95% CI: 
0.94-0.99) og fodundersøgelse (RR 0.96, 95% CI: 0.93-0.99). Desuden havde denne 
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gruppe en lavere risiko for at modtage en høj behandlingskvalitet for diabetes (RR 
0.91, 95% CI: 0.88-0.95) sammenlignet med diabetespatienter uden skizofreni. 
Stofmisbrug og behandling på ambulatorier med et lavt kontaktvolumen af 
diabetespatienter var associeret med en utilstrækkelig behandlingskvalitet for diabetes 
blandt diabetespatienter med skizofreni.  
STUDIE II 
Studie II omfattede 36.817 indlagte og ambulante patienter med nydiagnosticeret 
hjertesvigt, hvoraf 108 havde komorbid skizofreni. Resultaterne påviste, at 
nydiagnosticerede hjertesvigtpatienter med skizofreni havde en lavere risiko for at 
modtage 1 ud af 7 vurderede procesindikatorer for hjertesvigt, herunder behandling 
med betablokker (RR 0.87, 95% CI: 0.79-0.97). Disse patienter havde tillige en lavere 
risiko for at modtage en høj behandlingskvalitet for hjertesvigt (RR 0.66, 95% CI: 
0.48-0.91) end nydiagnosticerede hjertesvigtpatienter uden skizofreni. En lav GAF-
score var associeret med en mangelfuld behandlingskvalitet for hjertesvigt blandt 
nydiagnosticerede hjertesvigtpatienter med skizofreni. Nydiagnosticerede 
hjertesvigtpatienter med skizofreni havde en større risiko for 1-års mortalitet (justeret 
hasard ratio (HR) 2.85, 95% CI: 1.59-5.09), men ikke en større risiko for 4-ugers 
genindlæggelse sammenlignet med nydiagnosticerede hjertesvigtpatienter uden 
skizofreni.          
STUDIE III 
Studie III inkluderede 72.692 indlagte og ambulante KOL-patienter, hvoraf 621 også 
havde en diagnose med skizofreni. Resultaterne viste, at KOL-patienter med 
skizofreni havde en lavere risiko for at modtage 1 ud af 9 evaluerede procesindikatorer 
for KOL, herunder behandling med langtidsvirkende inhaleret bronkodilatator enten 
som LAMA eller LABA (RR 0.92, 95% CI: 0.87-0.98). Denne population havde den 
samme risiko for at modtage en høj behandlingskvalitet for KOL (RR 0.95, 95% CI: 
0.87-1.03) sammenlignet med KOL-patienter uden skizofreni. Det mandlige køn var 
associeret med en utilstrækkelig behandlingskvalitet for KOL blandt KOL-patienter 
med skizofreni. KOL-patienter med skizofreni havde en større risiko for 30-dages 
mortalitet (justeret odds ratio (OR) 1.27, 95% CI: 1.01-1.59), men ikke en større risiko 
for 30-dages genindlæggelse end KOL-patienter uden skizofreni.      
KONKLUSION 
Patienter med skizofreni havde en lavere risiko for at modtage flere procesindikatorer 
for diabetes, hjertesvigt og KOL, men de absolutte forskelle var generelt beskedne. 
Prædiktorerne for denne mangelfulde behandlingskvalitet omfattede patient- og 
systemrelaterede faktorer. Patienter med skizofreni havde dog en betydelig højere 
risiko for mortalitet efter første hospitalskontakt med nydiagnosticeret hjertesvigt 
samt efter indlæggelse for akut KOL-exacerbation. Yderligere tiltag er derfor 
påkrævet for at reducere den høje mortalitet af hjertesvigt og KOL blandt patienter 
med skizofreni.   
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CHAPTER 1. INTRODUCTION  
The substantial morbidity and disability experienced by patients with schizophrenia 
represent a major global health challenge. Improving the symptomatic treatment of 
the disorder has therefore received much needed attention since the term 
schizophrenia was introduced at the beginning of last century, and it remains an 
important goal (1,2). However, decades of neglecting the medical health in this 
vulnerable population has contributed to alarmingly high mortality rates. Patients with 
schizophrenia are estimated to have a reduced life expectancy of 10-20 years 
compared to the general population (3-9). Although intentional self-harm and 
accidents may partly explain the excess mortality, the dominant part is attributed to 
medical comorbidities, including diabetes, cardiovascular disease and respiratory 
disease (4-7,9). This emphasizes the crucial role of ensuring effective prevention, 
early diagnosis and optimal treatment of these potentially fatal medical comorbidities. 
There is, however, a shortage of published research, particularly from universal health 
care settings, to clarify whether patients with schizophrenia receive sufficient care for 
their comorbid diabetes, cardiovascular disease and respiratory disease. Despite 
emerging evidence indicating deficiencies in care (10-24), the magnitude of the 
problem varies considerably. In addition, the internal and external validity of the vast 
majority of existing studies is hampered by methodological limitations, including lack 
of detailed data on the care provided, non-population-based study designs and 
financial incentives. 
 
For more than a decade, a nationwide multidisciplinary initiative has systematically 
monitored the quality and equity of care provided by the public and mainly tax-
financed Danish health care system (25-27). The universal health coverage ensures, 
in principle, free and equal access to hospital care for all Danish residents regardless 
of their socioeconomic status (28). This singular setting creates a unique opportunity 
to elucidate whether equal access also implies equal and sufficient medical care for 
patients with a serious mental disorder such as schizophrenia. Based on 
comprehensive information from Danish nationwide registries, this thesis aims to 
examine the important interrelations between schizophrenia and the quality of care for 
diabetes, heart failure and chronic obstructive pulmonary disease (COPD) 
respectively.     
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CHAPTER 2. BACKGROUND 
The following chapter will introduce schizophrenia and its association with medical 
comorbidities and increased mortality. Subsequently, a literature review will examine 
the existing evidence on the quality of care for diabetes, heart failure and COPD 
among patients with schizophrenia. Finally, limitations of the identified publications 
will be described, as well as the features that make Denmark a suitable setting for 
gaining further insight into the area.   
2.1. SCHIZOPHRENIA 
Schizophrenia is a severe and debilitating mental disorder. Approximately 1% of the 
population worldwide presents with the disorder, and the global incidence rate has 
been estimated to be 15.2 per 100,000 persons (29-32). 
Although the etiology of schizophrenia remains complex and not fully clarified, 
genetic predisposition, including a family history of schizophrenia, and environmental 
factors, involving an urban place of birth and low social class, have been identified as 
the important determinants. The predisposing genes, the models of genetic 
transmission and the factors related to social class, however, need further verification 
(29-31,33).  
The disorder affects roughly equal numbers of males and females. Males typically 
present with the first psychotic episode of schizophrenia between their early and mid-
20s whilst females present in their late 20s (29-32). The course of the disorder varies, 
with an estimated duration of at least 6 months. About 25-45% of patients with 
schizophrenia recover after one or more episodes or show an almost complete 
remission; 35-50% display a moderate course with different lengths of exacerbations 
and degrees of remissions, whilst 20-25% experience increasing disability and chronic 
symptoms (29-31,34). The majority of patients with schizophrenia therefore require 
long-term maintenance care. Psychopharmacological treatment, including 
antipsychotic medication, is generally used to reduce symptoms of the disorder, whilst 
psychosocial interventions, comprising e.g. psychoeducation, cognitive behavioural 
therapy and family interventions, are provided to improve functioning and quality of 
life. Furthermore, treatment of schizophrenia often involves health monitoring and 
support programmes to promote recovery, although variations occur between mental 
health care systems (34-38).  
As a consequence of its early onset and commonly chronic nature, schizophrenia 
imposes a high economic burden on society. Loss of productivity and unemployment 
due to morbidity and mortality, i.e. indirect costs, contribute most to the expenditures 
associated with the disorder.  However, the amount spend on providing care, i.e. direct 
costs, are likewise significant, accounting for 1.5-3% of the total health care expenses 
(39,40).    
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2.1.1. MENTAL CONSEQUENSES 
Schizophrenia has a wide range of psychological, social and cognitive symptoms. 
Although no symptom is entirely pathognomonic, a number of positive and negative 
symptoms generally characterize the disorder. The positive symptoms include 
distortion or exaggeration of normal brain functions such as disorganized speech and 
behaviour, hallucinations and delusions. In contrast, negative symptoms comprise 
loss or decrease of normal functions, such as inability to initiate and preserve in 
work or social activities, a diminished range of emotional expression and poverty of 
speech (29-31). Furthermore, patients with schizophrenia often experience deficits 
in several cognitive domains, including memory, attention and learning, which is a 
core feature of the disorder (41).  
 
Concurrent with the characteristic symptoms, schizophrenia is commonly associated 
with additional mental comorbidities (29,42). Approximately 50% of all patients 
with schizophrenia are subject to comorbid depression and substance abuse, which 
further disturbs the clinical picture. Depressive symptoms can cause more psychotic 
relapses and secondary negative symptoms, whilst substance abuse can increase 
social disability and worsen positive psychotic symptoms (29,42). Schizophrenia is 
one of the leading causes of disability in the world (43,44). 
 
2.1.2. MEDICAL CONSEQUENSES 
In addition to the mental burden and suffering, the medical ramifications of 
schizophrenia likewise contribute to the debility. Of particular note is the increased 
risk of premature mortality associated with medical comorbidities. Compared to the 
general population, patients with schizophrenia have a 2-3 times higher mortality rate, 
which is equivalent to 10-20 years’ shortened life expectancy (3-9). Over recent 
decades, this mortality gap has persisted, despite the fact that advances in e.g. public 
health and medical innovations have increased the lifespan of the general population 
(3,8,45,46). 
The elevated mortality rates associated with schizophrenia are found for almost all 
causes (6,7,47,48). Overall, approximately one third can be explained by unnatural 
causes, including accidental death and suicide, whilst two thirds are attributable to 
natural causes involving medical comorbidities (4-7,9). In particular, diabetes, 
cardiovascular disease and respiratory disease, including COPD, have been identified 
as predominant and important contributors to the reduced longevity of patients with 
schizophrenia (5-9,49). The underlying causal mechanisms for these medical 
comorbidities are multifactorial, but often related to a higher prevalence of potentially 
modifiable risk factors.  
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Patients with schizophrenia are especially prone to weight gain and the metabolic 
syndrome, comprising hypertension, abdominal obesity, low high-density lipoprotein 
(HDL) cholesterol, hyperglycaemia and elevated triglycerides induced by their 
antipsychotic treatment (50-53). Unfavourable lifestyle behaviours, including poor 
diet, smoking, substance abuse and physical inactivity, are likewise more predominant 
in this group compared to the general population (29,54-57). This association is 
potentially explained by the characteristic symptoms of schizophrenia, cognitive 
impairment and low socioeconomic status.  More recently, a genetic predisposition 
has been linked to the development of medical comorbidities. Biological markers, 
including e.g. diminished telomere length, might affect physiological changes 
occurring at an earlier stage. Schizophrenia may thus be a syndrome of accelerated 
aging, causing age-related disorders such as diabetes and cardiovascular disease 
(58,59). Shared susceptible genetic components between schizophrenia and Type 2 
diabetes have also been suggested as potential risk factors (60,61). However, the 
pathogenetic association in schizophrenia is still elusive, and all the treatment, 
behavioural and genetic factors mentioned mainly serve to clarify the frequently 
observed medical comorbidities among patients with schizophrenia (48,62-64). What 
is certain is that this vulnerable population merit special health care attention in the 
management of their medical comorbidities. In particular, the leading and important 
medical causes to the devastating years of life lost, including diabetes, cardiovascular 
disease and respiratory disease, warrant an urgent call to action, and a duty for the 
health care systems to provide a better quality of care.   
2.2. LITERATURE REVIEW 
To clarify whether patients with schizophrenia receive the important treatment for 
their most critical medical comorbidities, a literature search was performed on the 
association between schizophrenia and the quality of care for diabetes, heart failure 
and COPD respectively. 
2.2.1. SEARCH STRATEGY 
Scientific publications were searched for in PubMed, Embase, PsycINFO and Cinahl 
based on a combination of free-text, MESH terms and Cinahl Headings, such as 
Schizophrenia, Comorbidity and Healthcare disparities. The search strategy included 
literature in English and Scandinavian languages with no restrictions on publication 
year (Appendix A). Studies located from the search strategy were initially excluded if 
the title, abstract or full text was considered non-relevant. Publications based on non-
comparative results, weak and unclear designs or small study populations were further 
excluded (Appendix B). A literature checklist from the Danish Health Authority was 
used to critically assess the scientific content of the remaining identified relevant 
publications (65). Moreover, the reference lists of the included studies were browsed 
to identify further relevant publications. Additional literature and information not 
indexed were located from the internet, including google.com, who.com (World 
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Health Organization) and sundhed.dk (the public Danish Healthcare Services). The 
final search for scientific publications, literature and information was conducted in 
November 2016.       
2.2.2. QUALITY OF DIABETES CARE 
The literature search identified seven relevant publications examining the quality of 
diabetes care for a variety of mental disorders, including schizophrenia (10-14,66,67). 
An overview of the studies located, listed by publication year, is presented in Table 1. 
The assessed quality of care measures included a pathology test (glycated 
haemoglobin (HbA1c), lipid, albuminuria, creatinine), body mass index (BMI) and 
blood pressure measurement, use of antidiabetic medication, flu vaccination provided, 
smoking cessation counselling as well as eye and foot examination.  
Three studies from the USA, United Kingdom and Germany found that patients with 
and without a serious mental illness had a comparable or very similar chance of 
receiving tests for HbA1c, lipid, albuminuria and creatinine, recordings for BMI, blood 
pressure, smoking history and smoking cessation counseling as well as retinal 
screening, flu vaccination and antidiabetic medication (14,66,67). An additional US 
study also detected no differences in diabetes care defined as offering test for HbA1c 
as well as an eye and foot examination among patients with and without a major 
affective disorder, psychotic disorder or posttraumatic stress disorder. However, the 
study found that patients with a substance use disorder were less likely to receive 
retina (63.9% vs 71.0%) and foot sensory examination (74.7% vs 77.5%) compared 
to patients with no mental disorders (10).  The three remaining studies from Australia 
and the USA documented an association between mental disorders and a deficient 
quality of diabetes care for all performance measures of care assessed (11-13). One of 
the publications set in USA demonstrated that patients with a mental disorder had a 
lower chance of receiving the four examined measures of diabetes care, including 
HbA1c test (Odds ratio (OR) 0.88, 95% CI: 0.86-0.89), eye examination (OR 0.73, 
95% CI: 0.72-0.74), low-density lipoprotein (LDL) screening (OR 0.88, 95% CI: 
0.86-0.89) and medical attention for nephropathy (OR 0.96, 95% CI: 0.94-0.99) than 
patients with no mental disorders (13). Similar inequalities were shown in another 
study conducted in the USA, indicating insufficient quality of care for HbA1c test and 
low-density lipoprotein cholesterol (LDL-C) measurement as well as eye examination 
(11). Failure to meet recommended testing for HbA1c, microalbuminuria and blood 
lipid among mental health clients was likewise revealed in the Australian study (12).    
Overall, the literature search demonstrated varying results and uncertainty about the 
quality of diabetes care among patients with a mental disorder, including 
schizophrenia. 
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2.2.3. QUALITY OF HEART FAILURE CARE 
The literature search located no publications specifically assessing the quality of heart 
failure care in patients with schizophrenia. However, 11 relevant studies addressed 
the quality of care for a broader range of cardiovascular diseases among patients with 
mental disorders, including schizophrenia (15-24,68). Table 2 presents an overview 
of the literature identified, listed by publication year.   
The quality of care measures examined included cardiovascular procedures and 
medication, laboratory health measurements and smoking cessation counseling. Of all 
the publications, only one study from the USA found no significant differences for 
any of the observed measures in the quality of care for acute coronary syndromes 
among patients with and without severe mental illness (68). The study compared the 
quality of care as receipt of cardiac catheterization (P value (p) =0.14), percutaneous 
coronary intervention (PCI) (p=0.10), coronary artery bypass graft (CABG) (p=0.61) 
and prescription rates for aspirin (p=0.38), angiotensin-converting enzyme inhibitors 
(ACE)/Angiotensin II receptor blockers (ARB) (p=0.31) and beta-blockers (p=0.19) 
at hospital discharge (68). Three other US studies found a difference in only one key 
area of care (16,18), or found mixed results (15). In these studies, patients with a 
mental disorder hospitalized with acute myocardial infarction (AMI) were less likely 
to undergo diagnostic angiography (Relative risk (RR) 0.90, 95% CI: 0.83-0.98) (18) 
and to receive reperfusion therapy at hospital discharge (RR 0.87, 95% CI: 0.79-0.95) 
(16) than patients without a mental disorder. These studies found no difference in care 
defined as receiving thrombolysis at arrival, percutaneous transluminal coronary 
angioplasty (PCTA), CABG and smoking cessation counseling during the index 
hospitalization, and cardiac medication, including beta-blockers, ACE inhibitors and 
aspirin at hospital discharge (15,16,18).   
The remaining seven identified publications from Australia, Canada, Denmark, Israel 
and Taiwan demonstrated deficient quality of cardiovascular care in all (17,20-24) or 
almost all (19) examined measures of cardiovascular care among patients with a 
mental disorder. A Danish nationwide study compared the rates of invasive cardiac 
procedures after the first hospital contact for heart disease among patients with and 
without a severe mental disorder. Patients with a severe mental disorder younger than 
70 years old received lower rates of CABG and PTCA within 1 month (1.6% vs 
2.96%), 1 year (3.76% vs 7.90%) and 5 years (7.04% vs 12.27%) of contact compared 
to patients without a severe mental disorder. Similar results were found for patients 
with a severe mental disorder 70 years or older (20). The studies from Australia, 
Canada, Israel and Taiwan also found inadequate care defined as receiving CABG 
and PCTA as well as other cardiac procedures, including coronary artery obstruction, 
arterial implant, cardiac catheterization, cerebrovascular arteriography and 
percutaneous coronary intervention, in patients with mental disorder compared to 
those without (17,19,21-24).  
In summary, the majority of the identified relevant publications suggested inferior 
quality of cardiovascular care among patients with mental disorders, although the 
magnitude varied.  
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2.2.4. QUALITY OF COPD CARE 
The literature search identified no publications on the quality of COPD care in patients 
with mental disorders in general, just as no studies examining the quality of care for 
other respiratory disorders were identified. It therefore remains unknown whether 
patients with schizophrenia receive adequate care for their COPD comorbidity.  
2.2.5. SUMMARY AND LIMITATIONS OF THE LITERATURE IDENTIFIED 
In summary, the existing evidence on the association between schizophrenia and the 
quality of care for diabetes, heart failure and COPD is sparse, inconclusive or lacking. 
The literature search identified seven relevant studies assessing the care adequacy for 
diabetes, including four publications demonstrating equal or almost comparable levels 
of care among patients with and without mental disorders (10,14,66,67), and three 
studies showing suboptimal care for patients with a mental disorder (11-13). However, 
organizational and financial differences in the health care systems as well as 
methodological limitations need to be taken into consideration when interpreting the 
results. In the four studies with no appreciable differences in diabetes care, one 
German publication also included patients covered by private health insurance (14), 
whilst two US studies comprised patients from the US Veterans Health 
Administration only (10,66). The fourth study from the United Kingdom examined 
patients seen by general practitioners (67). Of the remaining three publications 
demonstrating insufficient diabetes care for patients with a mental disorder, only one 
Australian study was conducted in a universal health care system (12). The other two 
publications originated in the USA and included members aged 65 years or younger 
(13) or predominantly male patients receiving care in the Veterans Health 
Administration (11). These factors may therefore partly explain the inconsistencies 
between the studies and affect the generalizability of the results. The main limitations 
of the existing publications in diabetes care include the non-population-based study 
designs (only one Australian study examined the population of Western Australia 
(12)), the more than 10 years old data (10,11,66,67), the limited follow-up period 
(10,11,13,66), and the potential influence of unaccounted-for confounding factors.  
Similar financial differences between the health care systems and methodological 
limitations characterize the 11 located relevant studies addressing the quality of 
cardiovascular care, including four publications demonstrating no differences in care 
or diverging results between patients with and without mental disorders (15,16,18,68), 
and seven studies indicating deficient quality of care for patients with a mental 
disorder (17,19-24). Of the four US studies with no or inconclusive differences in 
cardiovascular care, two publications included only patients aged 65 years or older 
(15,16), whilst the other two studies covered mainly male patients with access to care 
through the US Veterans Health Administration (18,68), which complicates 
generalizability across health care systems. The remaining seven studies originating 
in Australia, Canada, Denmark, Israel and Taiwan showing inadequate quality of care 
for patients with a mental disorder were all executed in universal or near-universal 
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health care systems (17,19-24). Different inclusions of cardiovascular disease, quality 
measures and psychiatric disorders, however, complicate a direct comparison across 
the studies. Overall, the methodological limitations include lack of information on 
patient characteristics, including severity of cardiovascular disease or clinical 
decision-making on cardiac procedures in some studies as well as shortage of detailed 
data on the care provided and population-based study designs. Of the 11 identified 
publications in cardiovascular care, only one Danish study based their results on an 
entire population (20).     
Finally, no publications were found elucidating the quality of care for COPD or other 
respiratory diseases among patients with a mental disorder, including schizophrenia. 
The literature identified therefore strongly suggests a continued need for population-
based studies with detailed data on the care provided, in particular from universal 
health care settings, to clarify the association between schizophrenia and the quality 
of care for diabetes, heart failure and COPD.   
2.3. DENMARK AS A SETTING FOR STUDYING MEDICAL CARE 
FOR PATIENTS WITH SCHIZOPHRENIA 
In Denmark, health equity is a stated priority of the public and mainly tax-financed 
health care system that covers the entire population of 5.7 million residents. The 
universal health coverage ensures free and equal access to care in public health 
services for all Danish citizens regardless of their socioeconomic status (28). The 
health care system consists of a primary and secondary sector. While general health 
problems are typically treated by general practitioners in the primary sector, patients 
requiring specialized treatment are referred to public hospitals defined as the 
secondary sector. The public hospitals cover both in- and outpatients as well as 
emergency room contacts (69).  
 
All Danish residents are assigned a unique ten-digit civil registration number, which 
follows the persons forever (70,71). This number is used to record each patient contact 
with the health care system in public registries and ensures unambiguous linkage of 
information at the individual level across various data sources. The variables collected 
in relation to the care provided include e.g. date of contact, diagnostic and procedure 
codes as well as the quality of care defined as receiving guideline-recommended 
disease-specific performance measures of care (25,72). This setting and the 
availability of comprehensive health care datasets in Denmark create an exceptional 
opportunity to examine whether equal access also implies equal and sufficient medical 
care for patients with serious mental disorders such as schizophrenia.  
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CHAPTER 3. AIMS AND HYPOTHESES  
The thesis aims to examine the association between schizophrenia and the quality of 
care for diabetes, heart failure and COPD in Denmark. This goal is investigated in 
three nationwide population-based cohort studies with the following objectives: 
 
3.1. STUDY I 
i. To compare the quality of diabetes care as reflected by meeting guideline-
recommended process-performance measures of care among patients with 
and without schizophrenia 
ii. To identify potential patient-, provider- and system-related predictors of 
quality of diabetes care among patients with schizophrenia 
3.2. STUDY II 
i. To compare the quality of heart failure care as reflected by meeting 
guideline-recommended process-performance measures of care among 
patients with and without schizophrenia 
ii. To identify potential patient-, provider- and system-related predictors of 
quality of heart failure care among patients with schizophrenia 
iii. To compare 4-week readmission and 1-year mortality following a first-time 
hospital contact with heart failure among patients with and without 
schizophrenia 
3.3. STUDY III 
i. To compare the quality of COPD care as reflected by meeting guideline-
recommended process-performance measures of care among patients with 
and without schizophrenia 
ii. To identify potential patient-, provider- and system-related predictors of 
quality of COPD care among patients with schizophrenia 
iii. To compare 30-day readmission and 30-day mortality following admission 
for an exacerbation of COPD among patients with and without schizophrenia 
 
It is hypothesized that patients with schizophrenia are less likely to receive guideline-
recommended diabetes, heart failure and COPD care compared to patients without 
schizophrenia, and that specific factors can predict these quality gaps. Moreover, 
schizophrenia is hypothesized to be associated with increased readmission and 
mortality rates of heart failure and COPD.   
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CHAPTER 4. METHODS 
The three studies included in the thesis were approved by the Danish Data Protection 
Agency (J.no. 2008-58-0028) and based on information from national population-
based registries.   
4.1. DATA SOURCES 
A description of the data sources applied is provided in the following, including the 
Danish Clinical Registries (the Danish Schizophrenia Registry (DSR), the Danish 
Adult Diabetes Registry (DADR), the Danish Heart Failure Registry (DHFR) and the 
Danish Registry for COPD (DrCOPD)), the Danish National Patient Register, the 
Danish Psychiatric Central Research Register and the Danish Civil Registration 
System (25-27,70-82). It is mandatory for all Danish public hospitals to report to these 
registries.    
4.1.1. THE DANISH CLINICAL REGISTRIES  
In 2000, a nationwide multidisciplinary quality improvement initiative was initiated 
with the objective to routinely monitor and continuously audit the quality of care 
delivered by the Danish health care system (25-27). During the subsequent years, 
population-based clinical registries were established to document and improve the 
care for selected important diseases, including schizophrenia (DSR), diabetes 
(DADR), heart failure (DHFR) and COPD (DrCOPD) (73-80). These diseases were 
prioritized on the basis of high incidence, severity and expenditure for the Danish 
health care services (26,27). For each disease, a number of specific performance 
measures of care set in accordance with recommendations from national clinical 
guidelines are collected at the level of the individual in the registries. A 
multidisciplinary expert group appointed by professional organizations and scientific 
societies developed the disease-specific performance measures of care and relevant 
prognostic factors also monitored in the registries. Potential changes, additions or 
omissions of the quality measures of care are discussed regularly to ensure the 
continued relevance of the standards to be met in clinical practice (25-27,73-80).   
All data in the DSR, DADR and DHFR are collected prospectively from 
documentation in medical records by using standardized registration forms with 
precise, simple and feasible data instructions (73-78). For patients with schizophrenia, 
the registration form is completed for inpatients at discharge from psychiatric 
hospitals, and once a year for outpatients treated at hospital outpatient clinics. The 
DSR provides a high coverage: records are available for 93% of all hospital inpatients 
and 92% of every hospital outpatient with schizophrenia. Almost all patients with 
schizophrenia seen in the secondary health care system can therefore be identified 
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from the DSR since its introduction in 2004 (73,74).  
Outpatients with diabetes have their registration form filled in once a year at the 
hospital specialized outpatient clinics responsible for their care. The DADR was 
initiated in 2005 and approximately 90% of all hospital outpatients with diabetes are 
recorded in the registry. General practitioners collect similar diabetes data; however, 
completeness is currently low (75,76). 
Quality of care data for heart failure in- and outpatients are recorded at their first-time 
hospital admission or hospital outpatient contact with heart failure as the primary 
diagnosis. The DHFR includes records of 84% of all hospital in -and outpatients with 
incident heart failure. Due to a high proportion of missing data in the DHFR in its first 
year of launching in 2003, this thesis only included data from 2004 onwards (77,78).  
All of the collected data on patients treated with schizophrenia, diabetes and incident 
heart failure at Danish public hospitals are securely transmitted via the internet to each 
disease-specific clinical registry (26,27).  
 
In contrast to the DSR, DHFR and DADR, data on COPD care are not directly 
reported to a separate clinical registry. The DrCOPD has been operative since 2008, 
and data are prospectively recorded at discharge, hospital transmission or death for 
inpatients with COPD, and as part of daily clinical routine for outpatients with COPD 
seen at hospital outpatient clinics. The COPD diagnosis in the DrCOPD has a positive 
predictive value of 92% for hospital inpatients and 86% for hospital outpatients. 
Outpatient data from general practitioners can also be obtained; however, data 
coverage remains incomplete. All data in the DrCOPD are reported entirely through 
diagnosis codes and codes for clinical procedures in the Danish National Patient 
Register (72,79,80). The DSR also decided to collect data via the Danish National 
Patient Register from 2012 onwards (73).  
4.1.2. THE DANISH NATIONAL PATIENT REGISTER 
The Danish National Patient Register has collected information on all somatic 
inpatient hospital contacts in Denmark since its establishment in 1977. From 1995 
onwards, all outpatient, emergency room and psychiatric hospital contacts have also 
been included in the registry. Data records include date and time of hospital contact, 
identification of the specific place of treatment, diagnoses and type of examination, 
treatment or surgical procedure. Each variable is allocated a structured and limited set 
of codes (72).     
4.1.3. THE DANISH PSYCHIATRIC CENTRAL RESEARCH REGISTER 
Since 1969, all psychiatric inpatients treated at Danish psychiatric hospitals have been 
recorded in the Danish Psychiatric Central Research Register. The register was 
expanded in 1995 to also include psychiatric patients seen at hospital outpatient clinics 
and emergency rooms, simultaneously becoming an integrated part of the Danish 
National Patient Register. The psychiatric data are transmitted monthly from the 
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Danish National Patient Register to the Danish Psychiatric Central Research Register. 
For each psychiatric patient treated, the register contains all diagnoses, dates of start 
and end of any treatment as well as the specific location of treatment (81,82).  
4.1.4. THE DANISH CIVIL REGISTRATION SYSTEM 
The Danish Civil Registration System was founded in 1969 and assigns a unique civil 
registration number to all Danish residents at birth or when taking up residence. The 
system maintains daily updated information on date and place of birth, location of 
residence, emigration or immigration and vital status (70,71).  
4.2. STUDY POPULATION 
The study populations of all three studies were identified from the Danish Clinical 
Registries.  
4.2.1. STUDY I 
Study I comprised all outpatients (≥18 years old) treated for diabetes at a hospital 
diabetes specialized outpatient clinic and recorded in the DADR between 1 January 
2005 and 31 December 2013. All diabetes contacts for each patient were included in 
the analysis. Diabetes referred to Type 1 diabetes, Type 2 diabetes, other types of 
diabetes and diabetes without specification defined according to the International 
Classification of Diseases version 10 (ICD-10) (E10.0-E11.9, E13.0-E14.9). At each 
diabetes contact, the patient was assigned the current clinical diagnosis by the treating 
outpatient clinic (75,76,83).   
4.2.2. STUDY II 
Study II included all in- and outpatients (≥18 years old) registered in the DHFR at 
first-time hospital contact (admission or outpatient contact) with heart failure as the 
primary diagnosis between 1 January 2004 and 31 December 2013. Each incident 
heart failure patient was thus only included once in the analysis, whether treated at a 
hospital department or outpatient clinic. Based on diagnoses made by cardiologists 
using the guidelines of the European Society of Cardiology, the DHFR includes the 
following ICD-10 codes for heart failure: I11.0, I13.0, I13.2, I42.0, I42.6, I42.7, I42.9, 
I50.0, I50.1, I50.9 (77,78,83).  
4.2.3. STUDY III 
Study III covered all in- and outpatients (≥30 years old) treated for COPD or an acute 
exacerbation of COPD at any hospital department and hospital outpatient clinic and 
recorded in the DrCOPD between 1 January 2008 and 31 December 2013. All COPD 
contacts for in- and outpatients were included in the analysis. The DrCOPD includes 
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inpatients with the following ICD-10 codes: DJ44.X as a primary diagnosis or DJ96.X 
or DJ13.X-DJ18.X as a primary diagnosis in combination with DJ44.X as a secondary 
diagnosis. For outpatients, the DrCOPD includes DJ44.X or DJ96.X in combination 
with DJ44.X as a secondary diagnosis. The physicians responsible for the care of the 
individual COPD patient performed the coding of the diagnosis (79,80,83).  
4.3. PATIENTS WITH SCHIZOPHRENIA 
By linkage with the DSR, all patients in the three study populations who also had 
comorbid schizophrenia were identified. Schizophrenia was defined as a recording in 
the DSR between 1 January 2004 and 31 December 2011 as either an in -or outpatient 
with schizophrenia (ICD-10 codes: F20.0-F20.99). A psychiatrist or a specialist 
clinical psychologist made the diagnosis of schizophrenia (73,74,83).  
Patients were excluded if schizophrenia was not recorded before their first recording 
of diabetes (N=29), incident heart failure (N=26) or COPD contact (N=16). To ensure 
coherence, patients were moreover excluded if they had >5 years between the 
recording for schizophrenia in the DSR and the subsequent registration in the DADR 
(N=23), DHFR (N=6) and DrCOPD (N=36).  
4.4. PREDICTORS OF MEDICAL CARE 
In all three studies, factors related to patients, providers and health care system were 
examined as potential predictors of the quality of care for diabetes, heart failure and 
COPD respectively.     
4.4.1. PATIENT-RELATED FACTORS 
The patient-related predictors were collected from the DSR, DADR, DHFR, DrCOPD 
and the Danish Psychiatric Central Research Register and included sex, age, abuse 
(alcohol or drug abuse (defined as illegal drugs, benzodiazepines or central 
stimulants)), duration of schizophrenia at the hospital contact for either diabetes, 
incident heart failure or COPD, and the Global Assessment of Functioning (GAF) 
scale ranging from 1 to 100. The GAF scale evaluates the overall psychosocial 
functioning of patients with schizophrenia, with 1 representing the poorest functioning 
and 100 the best functioning (73-82,84,85).   
4.4.2. PROVIDER-RELATED FACTORS 
To elucidate whether receiving an inadequate quality of care for schizophrenia is 
potentially associated with a subsequent deficient quality of care for diabetes, heart 
failure or COPD, the provider-related predictor included the quality of schizophrenia 
care delivered before the contact for diabetes, heart failure or COPD. Obtained from 
the DSR, Table 3 lists the definitions of the 12 process-performance measures of 
schizophrenia care assessed, covering the areas: diagnosing schizophrenia, 
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antipsychotic medical treatment, family intervention, psychoeducation, suicide risk 
assessment and post-discharge support (73,74). These process-performance measures 
were relevant for hospital in- and outpatients with schizophrenia, including incident 
patients. Patients with incident schizophrenia were defined as individuals diagnosed 
with schizophrenia within the past year. The quality of schizophrenia care was 
evaluated overall by dividing the number of process-performance measures of care 
received with the number of relevant measures for each patient with schizophrenia.  
Table 3 Definitions of the process-performance measures of schizophrenia care for hospital in- 
and outpatients with schizophrenia 
Process-performance measure Definition 
Assessment of psychopathology 
by a specialist in psychiatry 
Incident patients who are assessed for 
psychopathological characteristics by a specialist in 
psychiatry. 
Assessment of psychopathology 
by interview form 
Incident patients who receive a diagnostic interview 
with an established interview instrument, such as the 
Schedules for Clinical Assessment in Neuropsychiatry 
(SCAN) or the Operational Criteria Checklist for 
Psychotic Illness (OPCRIT). 
Assessment of cognitive 
function  
Incident patients who are administered cognitive testing 
by a psychologist. 
Assessment by a social worker Incident patients who are assessed for need for social 
support by a social worker, e.g. financial help to 
purchase medicine, help with changing housing or 
application for disability benefits.  
Antipsychotic medical 
treatment 
Patients who are prescribed antipsychotic medical 
treatment. 
Outpatient antipsychotic 
medical treatment 
Outpatients who are in medical treatment with more 
than one antipsychotic. 
Benzodiazepine medical 
treatment 
Outpatients who are in medical treatment with 
benzodiazepines, exclusive of benzodiazepine-related 
drugs (zolpidem, zopiclon, zaleplon). 
Contact with relatives Staff contact with the patient’s relatives. 
Psychoeducation Patients who receive psychoeducation. 
Professional support Patients with a GAF score ≤30 who are referred to 
post-discharge professional support in the patient’s own 
home, residential facilities or care homes.  
Psychiatric aftercare Patients who are referred to psychiatric aftercare, 
including outpatient treatment, contact to general 
practitioner or a private specialist, after discharge. 
Suicide risk assessment Patients who are assessed for suicide risk at discharge.  
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4.4.3. SYSTEM-RELATED FACTORS 
The system-related predictor comprised the contact volume of patients treated for 
diabetes, incident heart failure or COPD in the hospital departments and/or outpatient 
clinics.  
4.4.3.1 Study I 
Drawn from the DADR, the contact volume in Study I was defined as the average 
number of diabetes contacts in each hospital outpatient clinic per year from 2005 to 
2013 (75,76). The contact volume was divided into 4 quartiles, including low-volume 
contact (quartile 1, ≤519 diabetes contacts per year), medium-volume (quartile 2, 
>519-895 diabetes contacts per year), high-volume (quartile 3, >895-1620 diabetes 
contacts per year) and very high-volume contact (quartile 4, >1620 diabetes contacts 
per year). 
4.4.3.2 Study II 
The contact volume in Study II was collected from the DHFR and referred to as the 
average number of incident heart failure patients in the hospital departments and 
outpatient clinics per year from 2004 to 2013 (77,78). The four quartiles of the contact 
volume comprised: low-volume contact (quartile 1, ≤78 incident heart failure patients 
per year), medium-volume (quartile 2, >78-103 incident heart failure patients per 
year), high-volume (quartile 3, >103-120 incident heart failure patients per year) and 
very high-volume contact (quartile 4, >120 incident heart failure patients per year).  
4.4.3.3 Study III 
In Study III, the contact volume was obtained from the DrCOPD and defined as 
average COPD contacts in hospital departments and outpatient clinics per year from 
2008 to 2013 (79,80). The contact volume was distributed into the four qualities: low-
volume contact (quartile 1, ≤244 COPD contacts per year), medium-volume (quartile 
2, >244-424 COPD contacts per year), high-volume (quartile 3, >424-585 COPD 
contacts per year) and very high-volume contact (quartile 4, >585 COPD contacts per 
year). 
4.5. QUALITY OF MEDICAL CARE 
The quality of diabetes, heart failure and COPD care was defined as fulfillment of the 
individual disease-specific process-performance measures of care. Table 4, 5 and 6 
present the included performance measures of care by medical disease (75-80). 
Furthermore, the quality of care for each medical disease was summarized using an 
overall composite measure determined by dividing the number of received disease-
specific process-performance measures of care with the number of relevant measures 
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for each diabetes, incident heart failure and COPD patient.  
Throughout the study period, the set of disease-specific performance measures of care 
was modified as some performance measures were added whilst others were omitted. 
Therefore, the time periods for the measures varied, which was taken into account in 
the analysis.  
4.5.1. STUDY I 
Collected from the DADR, the quality of diabetes care was evaluated by 11 process-
performance measures of care relevant to hospital outpatients with diabetes (Table 4). 
The areas of diabetes care covered metabolic or glycemic regulation, monitoring and 
medical treatment for hypertension, lipids and albuminuria as well as eye and foot 
examination (75,76).  
Table 4 Definitions of the process-performance measures of diabetes care for hospital 
outpatients with diabetes 
Process-performance measure Definition 
Glycemic monitoring  Patients who have their glycated haemoglobin (HbA1c) 
level monitored, at least once a year.   
Medication: anti-diabetics  Type 2 diabetes patients with HbA1c ≥ 53 mmol/mol  
[7%] who are treated with anti-diabetic medication. 
Blood pressure monitoring Patients who have their blood pressure monitored, at 
least once a year. 
Medication: antihypertensive Patients with a blood pressure of >140/90 mmHg who 
are treated with antihypertensive medication. 
Cholesterol monitoring Patients over 30 years old who have their low-density 
lipoprotein (LDL) cholesterol monitored, at least every 
second year. 
Medication: lipid-lowering Type 2 diabetes patients over 40 years old with a LDL 
cholesterol > 2.5 mmol/l who are treated with lipid-
lowering medication. 
Screening for albuminuria Patients who are screened for albuminuria, at least 
every second year. 
Medication: ACE/ATII 
inhibitors 
Patients with micro- or macroalbuminuria who are 
treated with angiotensin-converting enzyme (ACE)/ 
angiotensin II receptor (ATII) inhibitors. 
Eye examination I Patients receiving an eye examination, at least every 
second year. 
Eye examination II Patients receiving an eye examination, at least every 
fourth year. 
Foot examination Patients receiving a foot examination, at least every 
second year. 
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4.5.2. STUDY II 
The quality of heart failure care was assessed using seven process-performance 
measures of care obtained from the DHFR and related to hospital in- and outpatients 
with incident heart failure (Table 5). The variables included diagnostic test, severity 
of symptoms, medical treatment, physical training and patient education (77,78).   
Table 5 Definitions of the process-performance measures of heart failure care and the clinical 
outcomes of heart failure for hospital in- and outpatients with incident heart failure 
Process-performance measure Definition 
Echocardiography Patients who undergo echocardiography.  
NYHA classification Patients who undergo New York Heart Association 
(NYHA) classification. 
Medication: ACE/ATII 
inhibitors 
Patients with reduced systolic function (Left 
Ventricular Ejection Fraction (LVEF) ≤ 40%) who are 
treated with angiotensin-converting enzyme 
(ACE)/angiotensin II receptor (ATII) inhibitors. 
Medication: beta-blockers Patients with reduced systolic function (LVEF ≤ 40%) 
who are treated with beta-blockers. 
Medication: aldosterone Patients with reduced systolic function (LVEF ≤ 35%) 
who are treated with aldosterone. 
Physical training Patients with reduced systolic function (LVEF ≤ 40%) 
who are referred to individual physical training. 
Patient education Patients with reduced systolic function (LVEF ≤ 40%) 
who start a structured patient education programme 
(including e.g. nutrition, physical training and medical 
treatment). 
Clinical outcome  Definition 
Readmission Patients who are acutely (i.e. not planned) readmitted 
for any cause within 4 weeks of discharge from a 
hospital department admission or outpatient clinic 
contact. 
Mortality Patients who die from any cause within 1 year of 
discharge from a hospital department admission or 
outpatient clinic contact. 
 
 
 
 
CHAPTER 4. METHODS 
47 
4.5.3. STUDY III 
The quality of COPD care was examined using nine process-performance measures 
of care relevant to COPD hospital outpatients only (Table 6). Classification of severity 
of disease, nutrition status, smoking history and cessation, COPD rehabilitation, 
medical treatment and inhalation technique were the measures assessed (79,80).   
Table 6 Definitions of the process-performance measures of COPD care and the clinical 
outcomes of COPD for hospital in- and outpatients with COPD 
Process-performance measure Definition 
Lung function Outpatients who have their forced expiratory volume in 
1 second in percent of predicted (FEV1 %) measured 
and recorded, at least once a year. 
Nutrition status Outpatients who have their body mass index (BMI) 
calculated and recorded, at least once a year. 
Dyspnea measurement  Outpatients who have their dyspnea measured and 
recorded using the Medical Research Council (MRC) 
scale, at least once a year. 
Smoking status Outpatients who have their smoking status determined 
and recorded, at least once a year. 
Smoking cessation Active smokers or recently stopped smoking 
outpatients who are encouraged to stop smoking, at 
least once a year. 
COPD rehabilitation Outpatients with an MRC level ≥ 3 who are offered 
participation in COPD rehabilitation, at least once 
every third year. 
Medication: LAMA/LABA Outpatients with an MRC level ≥ 2 who are treated 
with long-acting muscarinic antagonists (LAMA) or 
long-acting β2-agonists (LABA) including ultra-long-
acting β2-adrenoceptor agonists (ULTRA-LABA). 
Medication: inhaled steroids Outpatients with an MRC level ≥ 2 in a long-acting 
inhaled bronchodilator treatment and with a FEV1 
<60% who are treated with inhaled steroids. 
Inhalation technique Outpatients in inhaled medication treatment who have 
their inhalation technique checked with the relevant 
inhalers, at least once a year. 
Clinical outcome Definition 
Readmission Inpatients acutely admitted with a COPD exacerbation 
who are readmitted for any cause within 30 days of 
discharge. 
Mortality Inpatients acutely admitted with a COPD exacerbation 
who die from any cause within 30 days of admission. 
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4.6. CLINICAL OUTCOMES  
Data on the clinical outcomes of heart failure and COPD are also shown in Table 5 
and 6. The DADR does not document clinical outcomes for patients with diabetes 
(75,76).    
4.6.1. STUDY II 
Drawn from the DHFR and the Danish Civil Registration System, the clinical 
outcomes of heart failure comprised 4-week all-cause readmission and 1-year all-
cause mortality following a first-time hospital contact (admission or outpatient 
contact) with incident heart failure (Table 5) (70,71,77,78).    
4.6.2. STUDY III 
Information on clinical outcomes of COPD, including 30-day all-cause readmission 
and 30-day all-cause mortality following an admission for exacerbation of COPD, 
were obtained from the DrCOPD and the Danish Civil Registration System (Table 6) 
(70,71,79,80).  
4.7. STATISTICAL ANALYSIS 
All statistical analyses in the three studies were performed using STATA (version 
11.2 Special Edition). The 95% confidence intervals (CI) were corrected for clustering 
of each patient with diabetes, incident heart failure or COPD within the treating 
hospital department and/or outpatient clinic using robust estimates of variance. A two-
sided p-value ≤ 0.05 was considered to be significant.   
4.7.1. ANALYSIS OF QUALITY OF MEDICAL CARE 
For all three studies, binary regression was used to estimate the RR of adherence to 
the individual disease-specific process-performance measures of care and the overall 
composite measure among diabetes, incident heart failure and COPD patients with 
and without schizophrenia. Only patients recorded as relevant for the disease-specific 
performance measures of care according to the definitions were included in analysis. 
A high overall quality of diabetes, heart failure and COPD care was defined as having 
fulfilled at least 80% of the relevant recommended disease-specific process-
performance measures of care. This analysis was repeated to assess the robustness of 
the findings by using alternative cut points ranging from 60-90%.   
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All analysis were stratified according to patient characteristics, including sex, age, 
HbA1c level (for patients with diabetes), Left Ventricular Ejection Fraction (LVEF) 
level (for patients with incident heart failure) and dyspnea using the Medical Research 
Council (MRC) scale (for patients with COPD).    
4.7.2. ANALYSIS OF PREDICTORS OF MEDICAL CARE 
Binary regression was used in all three studies to examine separately the association 
between patient-, provider- and system-related predictors and the quality of care for 
each medical disease among diabetes, incident heart failure and COPD patients with 
schizophrenia. The potential predictors of medical care included sex, age, abuse, GAF 
score, duration of schizophrenia, quality of schizophrenia care and contact volume. 
Only predictors statistically significantly associated with the quality of diabetes, heart 
failure or COPD care in the univariable analysis were included in the mutually 
adjusted multivariable analysis. A high overall quality of schizophrenia care was 
defined as receiving at least 80% of the relevant process-performance measures of 
schizophrenia care. 
4.7.3. ANALYSIS OF CLINICAL OUTCOMES 
4.7.3.1 Study II 
In Study II, logistic regression was used to estimate the OR for 4-week all-cause 
readmission, whilst cox proportional hazards regression analysis was used to calculate 
the hazard ratio (HR) for 1-year all-cause mortality. The ORs and HRs were adjusted 
for patient characteristics, including sex, age, LVEF level, previous acute myocardial 
infarction (AMI), stroke or COPD, diabetes, treatment for hypertension, alcohol 
intake and smoking habits, to control for confounding. Due to several missing data, 
New York Heart Association (NYHA) classification was excluded from the adjusted 
multivariable analysis. The Kaplan-Meier estimator was used to plot cumulative 
mortality curves for 1-year all-cause mortality among incident heart failure patients 
with and without schizophrenia.    
4.7.3.2 Study III 
Logistic regression was also used in Study III to examine the OR for 30-day all-cause 
readmission and 30-day all-cause mortality. To control for confounding factors, ORs 
were adjusted for sex, age and the Charlson Index, which scores the number and 
severity of comorbidities for each patient (86). 
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CHAPTER 5. RESULTS 
The main results from the three studies included in the thesis will be presented in the 
following chapter. A detailed description of the results is reported in the appended 
papers for each study (Appendix C-E).  
5.1. STUDY I 
Study I comprised 83,813 diabetes patients with 302,638 diabetes contacts. A total of 
669 (0.79%) diabetes patients with 1,681 diabetes contacts also had schizophrenia 
recorded prior to their contact for diabetes. Compared to diabetes patients without 
schizophrenia, diabetes patients with schizophrenia were overrepresented with Type 
2 diabetes, were younger, more likely to be smokers and had higher HbA1c levels and 
BMI.   
5.1.1. QUALITY OF DIABETES CARE 
Table 7 presents the association between schizophrenia and the individual process-
performance measures of care as well as the overall quality of diabetes care (≥ 80% 
of all relevant process-performance measures of diabetes care fulfilled). Compared to 
diabetes patients without schizophrenia, diabetes patients with schizophrenia were 
less likely to receive 6 out of 11 individual process-performance measures, including 
blood pressure monitoring (RR 0.98, 95% CI: 0.96-0.99), treatment with 
antihypertensive drugs (RR 0.83, 95% CI: 0.70-0.97) and ACE/ATII inhibitors (RR 
0.72, 95% CI: 0.55-0.93), screening for albuminuria (RR 0.96, 95% CI: 0.93-0.99), 
eye examination at least every second year (RR 0.97, 95% CI: 0.94-0.99) and foot 
examination at least every second year (RR 0.96, 95% CI: 0.93-0.99) than diabetes 
patients without schizophrenia. The remaining process-performance measures were 
equally distributed among diabetes patients with and without schizophrenia. Meeting 
a high overall quality of diabetes care was also less likely among diabetes patients 
with schizophrenia (RR 0.91, 95% CI: 0.88-0.95) than among diabetes patients 
without schizophrenia. When applying alternative cut points of 60-90% to describe a 
high overall quality of diabetes care, the pattern remained, with RRs ranging between 
0.94 (95% CI: 0.91-0.97) and 0.82 (95% CI: 0.76-0.88). No systematic interaction 
was found when the individual process-performance measures and a high overall 
quality of diabetes care were stratified according to sex, age and HbA1c (data not 
shown).  
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Table 7 The relative risk (RR) of receiving the individual process-performance measures and 
a high overall quality of diabetes care among diabetes hospital outpatients with and without 
schizophrenia 
 Diabetes contacts 
with 
schizophrenia,  
N (%) 
Diabetes contacts 
without 
schizophrenia,  
N (%) 
Unadjusted RR 
(95 % CI) 
Individual performance 
measure 
   
Glycemic monitoring  1,227 (96) 241,955 (97) 0.98 (0.96-1.00) 
Medication: anti-diabetics  321 (98) 48,533 (98) 1.00 (0.99-1.02)  
Blood pressure 
monitoring 
1,178 (93) 234,424 (95) 0.98 (0.96-0.99) 
Medication: 
antihypertensive 
86 (66) 28,228 (80) 0.83 (0.70-0.97) 
Cholesterol monitoring 1,108 (94) 221,457 (95) 0.99 (0.97-1.01) 
Medication: lipid-
lowering 
38 (70) 7,161 (64) 1.09 (0.89-1.35) 
Screening for albuminuria 1,108 (88) 221,920 (91) 0.96 (0.93-0.99) 
Medication: ACE/ATII 
inhibitors 
27 (59) 7,656 (82) 0.72 (0.55-0.93) 
Eye examination I 1,075 (86) 214,593 (88) 0.97 (0.94-0.99) 
Eye examination II 1,155 (92) 226,515 (93) 0.99 (0.96-1.01) 
Foot examination 1,097 (87) 220,702 (91) 0.96 (0.93-0.99) 
Overall quality of care    
High* 956 (66) 197,412 (72) 0.91 (0.88-0.95) 
* Receiving 80-100% of relevant performance measures of diabetes care 
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5.1.2. PREDICTORS OF DIABETES CARE 
Drug abuse reduced the chance of receiving foot examination (adjusted for age: RR 
0.88, 95% CI: 0.79-0.99), whilst a very high clinic contact volume increased the 
chance of meeting a high overall quality of diabetes care (adjusted for age: RR 1.44, 
95% CI: 1.18-1.75) and treatment with ACE/ATII inhibitors (adjusted for duration of 
schizophrenia: RR 3.19, 95% CI: 1.80-5.65) among diabetes patients with 
schizophrenia. Young age and short duration of schizophrenia were also associated 
with a poorer quality of diabetes care, although the correlations were not as clear (data 
not shown).  
5.2. STUDY II 
Study II included a total of 36,718 incident heart failure patients, of which 108 
(0.29%) patients also had a diagnosis of schizophrenia before their first-time hospital 
contact with incident heart failure. The patient characteristics demonstrated that 
incident heart failure patients with schizophrenia were more likely to be smokers, 
younger and have a higher alcohol intake as well as a lower LVEF (≤ 35) than incident 
heart failure patients without schizophrenia.     
5.2.1. QUALITY OF HEART FAILURE CARE 
The association between schizophrenia and the individual process-performance 
measures of care as well as the overall quality of heart failure care is illustrated in 
Table 8. Incident heart failure patients with schizophrenia were less likely to receive 
1 out of 7 individual process-performance measures, including treatment with beta-
blockers (RR 0.87, 95% CI: 0.79-0.97) than incident heart failure patients without 
schizophrenia. No difference in heart failure care was found for the remaining 
process-performance measures among incident heart failure patients with and without 
schizophrenia. Incident heart failure patients with schizophrenia were less likely to 
receive a high overall quality of heart failure care (RR 0.66, 95% CI: 0.48-0.91) 
compared to those without schizophrenia. However, this pattern was not significant 
when a high overall quality of heart failure care was defined using alternative cut 
points ranging between 60% (RR 0.87, 95% CI: 0.75-1.01) and 90% (RR 0.65, 95% 
CI: 0.40-1.05). Stratifying the individual process-performance measures of care and a 
high overall quality of heart failure care by age, sex and LVEF displayed no evidence 
of systematic interaction (data not shown).  
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Table 8 The relative risk (RR) of meeting the individual process-performance measures and a 
high overall quality of heart failure care among incident heart failure hospital in- and 
outpatients with and without schizophrenia 
 Incident heart 
failure patients 
with 
schizophrenia,  
N (%) 
Incident heart 
failure patients 
without 
schizophrenia,  
N (%) 
Unadjusted RR 
(95 % CI) 
Individual performance 
measure 
   
Echocardiography 84 (86) 26,801 (87) 0.99 (0.91-1.07) 
NYHA classification 75 (74) 25,104 (73) 1.00 (0.89-1.13) 
Medication: ACE/ATII 
inhibitors 
69 (93) 20,415 (93) 1.00 (0.94-1.06) 
Medication: beta-blockers 56 (76) 18,892 (87) 0.87 (0.79-0.97) 
Medication: aldosterone 20 (37) 4,874 (35) 1.06 (0.75-1.49) 
Physical training 10 (13) 4,785 (21) 0.62 (0.36-1.08) 
Patient education 50 (68) 17,083 (76) 0.89 (0.75-1.05) 
Overall quality of care    
High* 26 (25) 13,188 (39) 0.66 (0.48-0.91) 
* Receiving 80-100% of relevant performance measures of heart failure care 
 
5.2.2. PREDICTORS OF HEART FAILURE CARE 
A GAF score ≥ 75 increased the chance of receiving treatment with beta-blockers 
(adjusted for age: RR 1.42, 95% CI: 1.15-1.76) and a high overall quality of heart 
failure care (adjusted for age: RR 3.41, 95% CI: 2.17-5.35) among incident heart 
failure patients with schizophrenia. The remaining potential predictors of heart failure 
care, including sex, age, abuse, duration of schizophrenia, quality of schizophrenia 
care and contact volume, were not independently associated with the chance of 
receiving treatment with beta-blockers and a high overall quality of heart failure care 
(data not shown).   
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5.2.3. CLINICAL OUTCOMES OF HEART FAILURE 
In the adjusted analysis for age, sex, LVEF, previous AMI, stroke and COPD, 
diabetes, in treatment for hypertension, alcohol intake and smoking habits, incident 
heart failure patients with schizophrenia did not have any statistically significantly 
increased risk of 4-week all-cause readmission (adjusted OR 1.77, 95% CI: 0.79-3.92) 
following a first-time hospital contact with incident heart failure compared to incident 
heart failure patients without schizophrenia. However, incident heart failure patients 
with schizophrenia had an increased risk of 1-year all-cause mortality (adjusted HR 
2.83, 95% CI: 1.59-5.04) (Table 9). A higher cumulative 1-year all-cause mortality 
for incident heart failure patients with schizophrenia compared to incident heart 
failure patients without schizophrenia is illustrated in Figure 1.  
Table 9 The odds ratio (OR) of 4-week all-cause readmission and the hazard ratio (HR) of 1-
year all-cause mortality following a first-time hospital contact with incident heart failure 
among hospital in- and outpatients with and without schizophrenia 
Clinical 
outcome 
Incident heart 
failure patients 
with 
schizophrenia,  
N (%) 
Incident heart 
failure patients 
without 
schizophrenia,  
N (%) 
Unadjusted 
OR/HR  
(95 % CI) 
Adjusted* 
OR/HR  
(95 % CI) 
4-week 
readmission 
13 (17) 2,445 (10) OR= 1.84 
(1.09-3.08) 
OR= 1.77 
(0.79-3.92) 
1-year 
mortality 
23 (22) 5,194 (15) HR= 1.57 
(0.94-2.59) 
HR= 2.83 
(1.59-5.04) 
* Adjusted for age, sex, LVEF, previous AMI, stroke and COPD, diabetes, in treatment for 
hypertension, alcohol intake and smoking habits 
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Figure 1 The Kaplan-Meier curves for 1-year all-cause mortality following a first-time hospital 
contact for heart failure among incident heart failure hospital in- and outpatients with and 
without schizophrenia 
 
 
 
5.3. STUDY III 
Study III contained 72,692 COPD patients with a total of 211,868 COPD contacts. 
Within this sample, 621 (0.85%) COPD patients with 1,502 COPD contacts also had 
a diagnosis of schizophrenia prior to their COPD contact. The characteristics indicated 
that COPD patients with schizophrenia had a higher BMI and were more likely to be 
younger, smokers and inpatients admitted for acute COPD exacerbation compared to 
COPD patients without schizophrenia.    
5.3.1. QUALITY OF COPD CARE 
Table 10 shows the association between schizophrenia and the individual process-
performance measures of care as well as the high overall quality of COPD care. 
Compared to COPD outpatients without schizophrenia, those with schizophrenia  
were less likely to receive 1 out of 9 process-performance measures, including 
treatment with long-acting muscarinic antagonists (LAMA) or long-acting β2- 
agonists (LABA) (RR 0.92, 95% CI: 0.87.-0.98). COPD outpatients with and without 
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schizophrenia had the same chance of receiving a high overall quality of COPD care 
(RR 0.95, 95% CI: 0.87-1.03), also when applying alternative cut points of 60-90% 
for defining a high overall quality of COPD care, with RRs ranging between 0.97 
(95% CI: 0.90-1.04) and 0.91 (95% CI: 0.79-1.04). When stratifying the individual 
process-performance measure of care and the high overall quality of COPD care by 
sex, age and the MRC scale, no evidence of systematic interaction was found (data 
not shown).   
Table 10 The relative risk (RR) of the adherence to the individual process-performance 
measures and a high overall quality of COPD care among COPD hospital outpatients with and 
without schizophrenia  
 COPD contacts 
with 
schizophrenia,  
N (%) 
COPD contacts 
without 
schizophrenia,  
N (%) 
Unadjusted RR 
(95 % CI) 
Individual performance 
measure 
   
Lung function 261 (72) 62,687 (75) 0.95 (0.88-1.02) 
Nutrition status 267 (73) 62,413 (75) 0.98 (0.91-1.04) 
Dyspnea measurement  261 (72) 61,082 (73) 0.97 (0.91-1.04) 
Smoking status 263 (72) 60,942 (73) 0.98 (0.92-1.06) 
Smoking cessation 173 (91) 17,746 (92) 0.99 (0.94-1.05) 
COPD rehabilitation 162 (90) 38,180 (90) 1.00 (0.95-1.06) 
Medication: 
LAMA/LABA 
123 (87) 24,484 (95) 0.92 (0.87-0.98) 
Medication: inhaled 
steroids 
91 (95) 17,734 (90) 1.05 (0.99-1.11) 
Inhalation technique 116 (75) 23,664 (77) 0.97 (0.88-1.08) 
Overall quality of care    
High* 244 (67) 58,686 (70) 0.95 (0.87-1.03) 
* Receiving 80-100% of relevant performance measures of COPD outpatient care 
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5.3.2. PREDICTORS OF COPD CARE 
Female sex increased the chance of receiving treatment with LAMA/LABA (adjusted 
for contact volume: RR 1.19, 95% CI: 1.02-1.39) among COPD patients with 
schizophrenia. The remaining predictors of COPD care were not independently 
associated with the chance of receiving LAMA/LABA treatment (data not shown).  
5.3.3. CLINICAL OUTCOMES OF COPD  
In the adjusted analysis for age, sex and Charlson index, COPD inpatients with 
schizophrenia did not have a statistically significantly increased risk of 30-day all-
cause readmission (adjusted OR 1.08, 95% CI: 0.92-1.28) following an admission for 
exacerbation of COPD. However, they had an increased adjusted risk of 30-day all-
cause mortality (adjusted OR 1.27, 95% CI: 1.01-1.59) compared to COPD inpatients 
without schizophrenia (Table 11).  
Table 11 The odds ratio (OR) of 30-day all-cause readmission and 30-day all-cause mortality 
following an admission for exacerbation of COPD among COPD hospital inpatients with and 
without schizophrenia  
Clinical 
outcome 
COPD contacts 
with 
schizophrenia,  
N (%) 
COPD contacts 
without 
schizophrenia,  
N (%) 
Unadjusted 
OR   
(95 % CI) 
Adjusted* 
OR  
(95 % CI) 
30-day 
readmission 
216 (21) 22,509 (20) OR= 1.07 
(0.90-1.26) 
OR= 1.08 
(0.92-1.28) 
30-day 
mortality 
101 (9) 12,739 (10) OR= 0.87 
(0.69-1.08) 
OR= 1.27 
(1.01-1.59) 
* Adjusted for age, sex and Charlson index 
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CHAPTER 6. DISCUSSION 
The findings from the three studies will be summarized in the following and 
methodological considerations will be discussed. Finally, the findings will be 
compared to the existing literature.   
6.1. SUMMARY OF FINDINGS 
Overall, in all three studies patients with schizophrenia appeared to have a worse 
physical health status and more unfavorable lifestyle behaviors than patients without 
schizophrenia. In addition, patients with schizophrenia had a lower chance of 
receiving diabetes, heart failure and COPD care measured by a number of clinical 
guideline recommendations than patients without schizophrenia, although the 
absolute differences in general were small. The predictors of not meeting the 
recommended care among patients with schizophrenia included drug abuse and low 
contact volume in diabetes care, a low GAF score in heart failure care, and male sex 
in COPD care. Patients with schizophrenia did not have a higher risk of early 
readmission, but experienced a substantially higher risk of mortality from both heart 
failure and COPD compared to patients without schizophrenia.  
6.2. METHODOLOGICAL CONSIDERATIONS  
All three studies in the thesis were designed as nationwide population-based cohort 
studies. The observational design may, however, have affected the accuracy and 
validity of the results due to potential systematic or random errors. Internal and 
external methodological considerations therefore need to be taken into account.   
6.2.1. INTERNAL VALIDITY  
6.2.1.1 Selection bias 
The study populations of all three studies were identified from national clinical 
registries (73-80). It is mandatory for all public hospitals to report to these registries, 
which ensures a generally high coverage of every patient treated for schizophrenia, 
diabetes, incident heart failure and COPD in the secondary Danish health care system, 
and an almost complete follow-up. Due to tax funding, treatment in public hospitals 
is free of charge for Danish residents (28). The probability of a systematic exclusion 
of patients with schizophrenia, diabetes, incident heart failure and COPD in the 
clinical registries is therefore considered to be limited.  
 
Only hospital outpatients with diabetes, in- and outpatients with incident heart failure 
and in- and outpatients treated for acute COPD exacerbation or COPD were included 
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in the three thesis studies. As a result, the quality of care remains unknown for 
diabetes, incident heart failure and COPD patients with schizophrenia seen 
exclusively by their general practitioner (GP). In this context, it should be noted that 
the majority of patients with Type 2 diabetes as well as patients with a primarily mild 
symptom severity of schizophrenia, heart failure and COPD are commonly treated by 
their GP and therefore potentially not included in the three study populations. 
Moreover, the interpretation of the results in the thesis should be considered taking 
into account that the impact of schizophrenia on diabetes, heart failure and COPD care 
may be considerable larger than reported in the three studies as patients with 
schizophrenia are frequently undiagnosed or untreated for their medical comorbidities 
(11,17,20,48,87). Consequently, the study populations included in the thesis may 
affect the generalizability of the findings.  
From the entire study population of patients with diabetes in Study I, 52 (0.06%) 
diabetes patients with comorbid schizophrenia were omitted from analysis due to 
exclusion criteria. In Study II, 32 (0.09%) incident heart failure patients with 
schizophrenia were excluded, whilst 52 (0.07%) COPD patients with schizophrenia 
were omitted from analysis in Study III. These small differences are considered not 
to have affected the results presented and therefore to be insignificant.  
6.2.1.2 Information bias 
All three studies in the thesis were based on information registered prospectively in 
Danish registries and independently of the study hypotheses, which reduces 
differential misclassification. However, data validity can always be called into 
question in registry-based studies. A large number of health professionals in routine 
clinical practice are involved in the data reporting to the DSR, DHFR, DADR and 
DrCOPD, which means that intra-and inter-observer variation as well as errors and 
differences in registration or coding practice may occur. However, extensive efforts 
are made to ensure data uniformity by designating key health care professionals in 
each hospital department or outpatient clinic to be responsible for data collection and 
accuracy. Moreover, validity is secured by detailed instructions and explicit data 
definitions, just as multidisciplinary structured audits are carried out regularly on a 
local, regional and national basis. The audits assess the quality of data critically and 
provide continuous feedback to hospital departments and outpatient clinics (25-27,73-
80). 
The primary exposure of interest in all three studies was the dichotomous presence of 
schizophrenia (yes/no). A possible inclusion of other psychiatric diagnoses in the 
comparison group of patients without schizophrenia may have diminished differences 
in the quality of diabetes, heart failure and COPD care as well as the differences in 
the clinical outcomes of heart failure and COPD. Disparities in care have also been 
demonstrated among diabetes patients with bipolar disorder and depression (12,13), 
and among patients with cardiovascular disease and bipolar disorder as well as 
affective disorder (15,23). Increased early readmission rates for ambulatory-care 
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sensitive conditions, including congestive heart failure exacerbation and COPD/adult 
asthma exacerbation, have also been shown among patients with a serious mental 
illness, including bipolar disorder (88).  
The secondary objective of interest, including patient-, (sex, age, abuse, duration of 
schizophrenia and GAF score), provider- (quality of schizophrenia care) and system-
related predictors (contact volume) of the quality of diabetes, heart failure and COPD 
care among patients with schizophrenia, was primarily categorized according to 
predefined cut points in all three studies. This may have introduced an additional 
potential bias towards the null if patients at a high risk of receiving the disease-specific 
process-performance measures of care were subcategorized together with patients at 
a low risk. The cut points may, in contrast, also have caused Type 2 errors. Different 
cut points were tested to reduce these biases. Furthermore, it should be noted that the 
patient-related predictor “duration of schizophrenia” may potentially be 
underestimated for some patients due to a restricted follow-up time in the registries 
used, including the DSR, DHFR, DADR, DrCOPD and the Danish Psychiatric Central 
Research Register (73-82). As a consequence of registration only starting in 1969, the 
maximum duration of schizophrenia for any patient was 44 years.  
The individual disease-specific process-performance measures of care and the high 
overall quality of diabetes, heart failure and COPD care were analysed dichotomously 
(received/not received) in all three studies in the thesis, as were the clinical outcomes 
of heart failure and COPD in Studies II and III, including readmission (yes/no) and 
mortality (dead/alive). Any potential errors in these performance measures are 
considered most likely to be non-differential misclassifications that bias the results 
presented toward the null value. However, it must be pointed out that the recording 
practice in standardized registration forms in Studies I and II could have caused 
missing data on the process-performance measures of care. Differential 
misclassification could potentially occur in these studies if the staff providing care 
were affected by e.g. difficulties in handling patients with a serious mental disorder 
such as schizophrenia in a somatic department or outpatient clinic. In this scenario, 
data on process-performance measures of care would be more likely to be missing 
among patients with schizophrenia. The results would therefore be biased and 
potentially underestimate differences in the quality of care between patients with and 
without schizophrenia. No particular differences in the missing performance measures 
were, however, found in Studies I and II.  
As all data are reported entirely through diagnosis codes and codes for clinical 
procedures in the DrCOPD, the process-performance measures of COPD care are only 
registered as being performed or not. This also means that it is not possible to 
determine whether a particular clinical procedure was not being performed or simply 
not being reported. However, Study III showed a similar percentage of missing data 
for the reported characteristics between COPD patients with and without 
schizophrenia as did Studies I and II. The missing values for the clinical outcome 
“readmission” were likewise almost equally distributed among patients with and 
without schizophrenia in Studies II and III. Data on the other clinical outcome 
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“mortality” in Studies II and III were obtained from the Danish Civil Registration 
System, which updates information daily on vital status of all Danish residents 
(70,71). Missing data on mortality were minimal, and misclassification of this 
outcome was therefore considered highly unlikely. Hence, the potential information 
biases in the thesis would most likely lead to non-differential misclassification and 
bias the presented results toward the null.  
6.2.1.3 Confounding 
Confounding is inevitably a relevant concern in all three studies included in the thesis 
due to their observational design. To address this issue, possible confounding factors 
were handled in the statistical analysis by stratification and adjustments.  
Explicit criteria were specified for the inclusion of diabetes, incident heart failure and 
COPD patients as well as for the performance measures in the DSR, DHFR, DADR 
and the DrCOPD (73-80). In principle, this means that all patients qualified as relevant 
to be provided with the recommended disease-specific processes-performance 
measures of care, irrespective of patient characteristics, psychiatric diseases and the 
treating hospital department and/or outpatient clinic. Confounding is therefore 
considered to be of minor importance for the study findings. Additional precautions 
were, however, undertaken by stratifying the analysis for sex, age and severity of the 
medical disease, including diabetes, heart failure or COPD, which did not 
considerably change the results resented in the thesis studies.  
A broad range of predictors of quality of care, including patient-, (sex, age, abuse, 
duration of schizophrenia and GAF score), provider- (quality of schizophrenia care), 
and system-related predictors (contact volume) were taken into account in all three 
studies. Nonetheless, several additional plausible underlying and complex 
mechanisms may influence and confound the quality of diabetes, heart failure and 
COPD care among patients with schizophrenia. Difficulties navigating between the 
psychiatric and somatic hospital departments and outpatient clinics, impaired or 
altered perception of physical symptom awareness, lack of strength to manage a 
somatic disease concurrent with a severe mental disorder, deficient communication 
skills or social vulnerability such as homelessness or isolation may constitute 
particular challenges among patients with schizophrenia. Fear, mistrust or a 
problematic relationship with the treating physician can also cause disengagement 
from care. The physician barriers may include provider variability, minimal 
experience with psychiatric patients or prejudice against these patients, whilst 
differences in the resources available, geographical variation as well as coordination 
and time constraints may serve as system-specific factors (89-91). These 
uncontrolled-for factors must consequently be taken into consideration when 
interpreting the results.     
The clinical outcomes in Studies II and III, including readmission and mortality, were 
adjusted for several important patient characteristics. After doing so, both the non-
significant crude estimates for increased mortality among patients with schizophrenia 
in Studies II and III changed to be significant after the adjustments. Still, the findings 
CHAPTER 6. DISCUSSION 
63 
may be affected by residual confounding due to misclassification or use of categorical 
variables while unaccounted-for confounding of unknown characteristics, e.g. length 
of hospital stay, cannot be disregarded. Nonetheless, the overall results are considered 
to be reasonably valid due to the accounted-for important characteristics.   
In all three studies, clustering of patients within the hospital departments and 
outpatient clinics was taken into account by the use of robust estimates of the variance. 
This was done to include unmeasured characteristics of the hospital departments and 
outpatient clinics potentially associated with both the quality and predictors of care as 
well as clinical outcomes.  
6.2.1.4 Precision 
The large sample sizes obtained from nationwide population-based registries improve 
the statistical precision in all three studies. Moreover, the 95% CI used throughout the 
thesis to express the random errors underlying the risk estimates were quite narrow, 
which indicates a high level of precision. However, some of the analysis of the 
predictors of care and clinical outcomes demonstrated relatively broad CIs. The point 
estimates should therefore be interpreted with more caution. The statistically 
significant results in all three studies also had a 5% risk of being chance findings.   
It should be noted that the absolute differences for the examined process-performance 
measures of diabetes, heart failure and COPD care among patients with and without 
schizophrenia in general were small in all studies included in the thesis. This indicates 
that the differences observed in care could be random. The sum of differences was, 
nonetheless, considerable in Studies I and II when all process-performance measures 
of care were taken into account. Furthermore, the clinical outcome, including 
mortality, yielded substantial differences in survival among patients with and without 
schizophrenia in Studies II and III. Overall, the findings in the thesis are therefore not 
likely to be explained by random errors.   
6.2.1.5 Summary of the internal validity 
The main strengths of all three studies include the nationwide population-based 
design, the large sample sizes and the comprehensive prospective data collection of 
the quality of diabetes, heart failure and COPD care. In addition, only patients relevant 
for the specific process-performance measures of care were included in the analysis, 
which reduces the risk of selection and information bias. Any potential 
misclassification in the thesis is most likely considered non-differential and biasing 
the findings toward the null. However, the results presented may be affected by 
residual or unaccounted-for confounding due to the observational study designs whilst 
some of the risk estimates had a moderate statistical precision. All findings in the 
thesis should therefore be interpreted only as associations and not as evidence of a 
causal relationship.  
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6.2.2. EXTERNAL VALIDITY 
All three studies were conducted under a universal and free-of-charge health care 
system using national registries with a generally high data coverage and completeness 
of patient recording as well as explicit data definitions. Population characteristics and 
management of medical comorbidities in patients with schizophrenia may differ 
across countries. These factors must be taken into consideration when comparing the 
findings presented in the thesis with previous publications from other health care 
settings.    
6.3. COMPARISON WITH THE EXISTING LITERATURE 
6.3.1. STUDY I 
Study I reported an association between schizophrenia and reduced risk of receiving 
a number of recommended process-performance measures of care, including 
treatment with antihypertensives, screening for albuminuria, blood pressure 
monitoring, eye and feet examination as well as a high quality of diabetes care. The 
findings of disparities in the quality of diabetes care among patients with 
schizophrenia are inconsistent with approximately half of the previous studies 
(10,14,66,67), but are in alignment with findings from the other half (11-13) (Table 
1). Only one of these publications, an Australian study, was conducted in a 
comparable universal health care setting (12). The authors of the Australian study 
reported that mental health clients were less likely to receive recommended routine 
pathology tests, including HbA1c, microalbuminuria and blood lipid, both at 1-year 
and during the entire follow-up period from 1990 to 2006 compared to non-mental 
health clients (12), which is in accordance with the inequalities reported in Study I. It 
can therefore be hypothesised that patients with schizophrenia may find the long 
intervals of time between diabetes follow-up checks particularly challenging to 
maintain, just as cognitive and social dysfunctions may hamper engagement, 
attendance and adherence in care (92,93).  
Study I showed that patient- and system-related factors were associated with the 
insufficient quality of diabetes care among diabetes patients with schizophrenia, 
including young age, drug abuse, short duration of schizophrenia and low contact 
volume. The clearest association was, however, found for drug abuse and contact 
volume, which might indicate that being a diabetes patient with schizophrenia and a 
concomitant drug abuse may engender major attendance issues with diabetes follow-
up checks. Moreover, outpatient clinics with a very high contact volume of diabetes 
patients may be characterized by better specialization, more resources and experience 
in managing psychiatric patients with special needs. Although the association between 
mental illness and the organizational structure of a health care system as a predictor 
of quality of care was not confirmed in other studies on diabetes care, similar findings 
have been shown for cardiovascular care. Previous US studies found that mentally ill 
patients were more likely to be admitted to low-quality somatic hospitals and to be 
CHAPTER 6. DISCUSSION 
65 
treated by low-quality cardiac surgeons for their cardiovascular comorbidities than 
non-mentally ill patients (94-96). Another US publication indicated that both patient-
, county- and state-specific factors predicted the quality of diabetes care among 
patients with diabetes and mental comorbidities. In this regard, young age, male sex, 
non-Hispanic race/ethnicity, low numbers of medical comorbidities (patient-specific 
factors), living in urban settings or primary care shortage areas (county-specific 
factors) and low reimbursement rates for physicians (state-specific factors) were 
associated with inadequate quality of diabetes care (13). It must, however, be pointed 
out that differences in financing and organization may complicate the generalizability 
of these findings across health care systems.    
Only patient- and system-related factors were identified as independent predictors of 
quality of care among diabetes patients with schizophrenia in this study. A recent 
Danish nationwide study documented improvements in the quality of schizophrenia 
care provided to inpatients with schizophrenia in Denmark between 2004 and 2011 
(97). In this period, the overall quality of schizophrenia care, reflected in the 
proportion of all relevant recommended process-performance measures of care 
provided to the patients, increased from 64% to 76% (97). This relatively high quality 
of schizophrenia care may potentially explain why the provider-related factor in this 
current study was not observed as a predictor of diabetes care.   
6.3.2. STUDY II 
Study II demonstrated an association between schizophrenia and reduced risk of 
receiving treatment with beta-blockers and a high quality of heart failure care. The 
majority of previous studies support similar findings of disparities in cardiovascular 
care among patients with a mental disorder, including schizophrenia (17,19-24) 
(Table 2). One of these publications, a Canadian study, likewise reported that 
ischaemic heart disease patients with comorbid psychosis were less likely to receive 
beta-blockers under universal health care compared to those without comorbid 
psychosis (19). The remaining process-performance measures of heart failure care 
explored in Study II were equally distributed among incident heart failure patients 
with and without schizophrenia. However, the differences in applied quality of care 
measures between this current study and the other publications in cardiovascular care 
complicate further direct comparison.   
Study II found that a high GAF score was associated with increased chance of 
receiving treatment with beta-blockers and a high quality of heart failure care among 
incident heart failure patients with schizophrenia. These findings may reflect that 
patients with a high GAF score usually experience a high level of functioning with 
only slight impairment, which may imply greater mental resources, understanding and 
ability to adhere to recommended medical treatment. This assumption is in accordance 
with previous studies indicating that positive attitudes toward medication and illness 
insight are associated with better medication adherence among patients with 
schizophrenia-spectrum disorders (93). Still, other issues need to be clarified before 
an actual conclusion can be drawn in this regard.   
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The finding of no early readmission among incident heart failure patients with 
schizophrenia is inconsistent with previous studies (88,98,99). It is, however, 
important to note that only one of these publications was conducted in a universal 
health care setting (88). This recent Danish nationwide study found an association 
between serious mental illness and increased risk of 30-day readmission for 
ambulatory-care sensitive conditions, including congestive heart failure exacerbation 
(88). In contrast, the finding of a higher 1-year mortality among incident heart failure 
patients with schizophrenia in this study is in accordance with several previous 
publications assessing the mortality rates of cardiovascular disease in patients with a 
mental illness (16,18-20). The most comparable study included a Danish publication 
demonstrating that patients with severe mental disorders had a higher risk of 1-year 
mortality following discharge from the first hospital contact with heart disease than 
patients without severe mental disorders (20). 
6.3.3. STUDY III 
Study III depicted an association between schizophrenia and reduced risk of receiving 
treatment with LAMA/LABA. However, COPD patients with and without 
schizophrenia had an equal risk of meeting the remaining process-performance 
measures of care included as well as a high quality of COPD care. Although no 
previous studies have examined the quality of care for COPD patients with and 
without schizophrenia, previous studies in primary care have demonstrated that 
compared to non-psychiatric patients, psychiatric patients were less likely to be asked 
about smoking status and to receive smoking cessation interventions as well as having 
BMI recorded (100-102). However, the magnitude of these differences varies 
considerably, with some studies finding no such deficits in the preventive care 
(103,104).  
It must be taken into consideration that only one process-performance measure of 
COPD care was found inadequate among patients with schizophrenia in this current 
study. Moreover, the difference in care for LAMA/LABA treatment between patients 
with and without schizophrenia was modest, which might indicate a chance finding. 
If the association genuinely reflects less probability of receiving LAMA/LABA 
treatment among COPD patients with schizophrenia, it points to the importance of 
improving the recommended pharmacological therapy in this group.    
Female sex was identified as an independent predictor of receiving LAMA/LABA 
among COPD patients with schizophrenia. It is possible, though not confirmed, that 
male patients in general may be more likely than female patients to lack energy, 
attention or willingness to attend regular COPD follow-up checks and therefore fail 
to meet the medical recommendations.   
Study III did not detect any increased risk of early readmission, after adjusting for 
age, sex and Charlson Index, among COPD patients with schizophrenia. This finding 
is inconsistent with previous publications (88,99), including a Danish nationwide 
study that demonstrated an association between serious mental illness and increased 
risk of 30-day readmission for ambulatory-care sensitive conditions, including 
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COPD/adult asthma exacerbation, after adjusting for demographics (age, sex and 
calendar year) or socio-economic factors (marital/partnered status, educational level, 
comorbidities) (88). The additional inclusion of adult asthma exacerbation in the 
analysis in the previous Danish study potentially explains the discrepancy between 
the results. Nonetheless, the finding of a higher risk of 30-day mortality among COPD 
patients with schizophrenia is in line with another population-based Danish study. In 
this particular study, patients with severe mental illness were found to have an 
increased risk of 30-day mortality after hospitalization for an infection, including 
pneumonia, compared with patients without a severe mental illness (105).   
6.3.4. SUMMARY OF COMPARISON WITH THE EXISTING LITERATURE 
In general, the findings in the existing literature is consistent with the findings from 
this thesis regarding a deficient quality of diabetes, heart failure and COPD care on 
specific parameters among patients with schizophrenia. However, the magnitude 
varies considerably and different quality of care measures and health care settings 
complicate a direct comparison. Moreover, other studies examining predictors of the 
quality of care in this population are sparse. The findings of no early readmission in 
Studies II and III among patients with schizophrenia are not in accordance with 
previous studies; however, the increased rates of mortality are supported by several 
previous publications. 
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CHAPTER 7. CONCLUSION 
This thesis provides greater insight into the interrelations between schizophrenia and 
the quality of diabetes, heart failure and COPD care in Denmark, which has a universal 
health care system. Based upon the findings from the three nationwide population-
based cohort studies included in the thesis, the following conclusions can be drawn.  
7.1. STUDY I 
Schizophrenia was associated with a lower chance of receiving 6 out of 11 examined 
process-performance measures of diabetes care, including blood pressure monitoring, 
treatment with antihypertensive drugs, including ACE/ATII, screening for 
albuminuria, eye examination at least every second year and foot examination, as well 
as a high quality of diabetes care. Predictors of deficient quality of care among 
diabetes patients with schizophrenia included drug abuse and low diabetes clinic 
contact volume. 
7.2. STUDY II 
Schizophrenia was associated with a lower chance of meeting 1 out of 7 assessed 
process-performance measures of heart failure care, including treatment with beta-
blockers, as well as a high quality of heart failure care. A predictor of inadequate 
quality of care among incident heart failure patients with schizophrenia included a 
low GAF score. Incident heart failure patients with schizophrenia experienced a 
higher 1-year mortality following the first-time hospital contact with incident heart 
failure, but not an increased risk of 4-week readmission.  
7.3. STUDY III 
Schizophrenia was associated with a lower chance of receiving 1 out of 9 examined 
process-performance measures of COPD care, including treatment with 
LAMA/LABA. The chance of meeting a high quality of COPD care was comparable 
among COPD patients with and without schizophrenia. A predictor of insufficient 
quality of care among COPD patients with schizophrenia included male sex. COPD 
patients with schizophrenia had no increased risk of 30-day readmission; however, 
they had a higher risk of 30-day mortality following admission for an exacerbation.  
In conclusion, the results showed that patients with schizophrenia had a lower chance 
of receiving a number of process-performance measures of diabetes, heart failure and 
COPD care compared to patients without schizophrenia. However, in general the 
absolute differences in care were small. Predictors of poorer quality of care included 
patient- and system-related factors among diabetes, incident heart failure and COPD 
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patients with schizophrenia. Patients with schizophrenia had a substantially increased 
risk of mortality following a first-time hospital contact with incident heart failure and 
after an admission for exacerbation of COPD. Interventions are therefore warranted 
to improve the survival of heart failure and COPD among patients with schizophrenia. 
Overall, the hypotheses of the studies included in this thesis were therefore partly 
confirmed. 
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CHAPTER 8. PERSPECTIVES 
For more than 50 years, it has been well-established that compared to the general 
population, patients with schizophrenia have substantially high mortality rates (4). 
Emerging evidence indicates that the major part of this mortality excess is due to 
medical comorbidities (4-7,9). Still, the findings of this thesis demonstrate a 
continuing health disparity in the survival of heart failure and COPD among patients 
with schizophrenia, even in a universal health care system with equity as a stated 
priority.  
Several questions, however, need to be further explored regarding the quality and 
predictors of care as well as the clinical outcomes of medical comorbidities among 
patients with schizophrenia. For instance, more information is needed to clarify 
whether this group receives deficient preventive care or experiences delays in medical 
screening and diagnostics of e.g. diabetes, heart failure and COPD. Moreover, it could 
be interesting to look into the health-seeking (or lack of) behaviour of patients with 
schizophrenia.  
Although the findings of this thesis suggest an almost sufficient fulfilment of heart 
failure and COPD treatment recommendations, the increased mortality rates of these 
medical comorbidities may indicate that patients with schizophrenia need more 
intensive and specialized care in the public somatic hospitals. Areas of interest for 
future research could therefore include an exploration of both the perspectives of the 
health care professionals and of the patients on the medical care provided. Potentially, 
the health care professionals in somatic hospitals may find that more time and 
resources as well as training in handling the specific needs of psychiatric patients are 
required in order for them to deliver ideal care. Likewise, patients with schizophrenia 
might state that the medical care provided does not fit their specific needs. Such an 
improved understanding of what constitutes optimal medical care could bring new 
insights into the area.  
More information is also warranted on the post-discharge medical care, which could 
prove to be inadequate since incident heart failure and COPD patients with 
schizophrenia did not experience any increased risk of early readmission despite 
increased mortality. Targeted interventions to improve the survival of patients with 
schizophrenia are highly needed, and it would therefore be relevant to examine the 
potential challenges of managing patients with schizophrenia after discharge from 
somatic hospitals. Such challenges might include concomitant drug or alcohol abuse, 
severe psychotic symptoms or social vulnerability, e.g. homelessness, as well as a 
range of other factors affecting the quality of post-discharge medical care among 
patients with schizophrenia. A further examination of the specific causes of death 
among incident heart failure and COPD patients with schizophrenia is needed to 
clarify the exact cause of death.      
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The need to focus attention on the medical ramifications of schizophrenia appears to 
apply to primary, secondary as well as tertiary care. This calls for an effectively 
collaborating and coordinated health care system in order to reduce the excess 
mortality in this vulnerable population. The Danish health care system is divided into 
psychiatric and somatic hospitals, with no integrated co-operation between the mental 
health care providers and the health care providers, neither in the somatic hospitals 
nor in the primary care settings, which is likely to complicate the management of 
medical comorbidities in patients with schizophrenia. Establishment of liaison 
somatic departments or outpatient clinics in the psychiatric hospitals would therefore 
be highly relevant as a means to coordinate and, to the extent possible, treat medical 
comorbidities, including e.g. diabetes, heart failure and COPD, among patients with 
schizophrenia.  
Finally, it must be noted that the latest version of Danish clinical guidelines for 
schizophrenia from 2004 was declared outdated in 2006 (34). Updated treatment 
recommendations are therefore warranted, including a greater focus on the medical 
comorbidities among patients with schizophrenia.  
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Appendix A. Literature search 
Table A1 The performed search strategies in PubMed, Embase, PsycINFO and Cinahl 
including English and Scandinavian language literature with no restriction on the publication 
year  
Database Search strategy 
PubMed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
#1: Schizophren*[tiab] 
#2: Schizophrenia[Mesh] 
#3: #1 OR #2 
 
#4: Metabolic syndrome X[Mesh] 
#5: Metabolic syndrome*[tiab] 
#6: Cardiovascular  diseases[Mesh] 
#7: Cardiovascular disease*[tiab] 
#8: Diabetes mellitus[Mesh] 
#9: Diabet*[tiab] 
#10: Pulmonary disease, chronic obstructive[Mesh] 
#11: Copd[tiab] 
#12: Chronic obstructive disease*[tiab] 
#13: Comorbidity[Mesh] 
#14: Comorbidit*[tiab] 
#15: #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 
OR #13 OR #14 
 
#16: Medical errors[Mesh] 
#17: Outcome assessment(Health care)[Mesh] 
#18: Healthcare disparities[Mesh] 
#19: Disparit*[tiab] 
#20: Inequalit*[tiab] 
#21: Inadequacy[tiab] 
#22: Diagnostic error*[tiab] 
#23: Underdetect*[tiab] 
#24: Misclassif*[tiab] 
#25: Misinterpret*[tiab] 
#26: #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 
OR #24 OR #25 
#27: #3 AND #15 AND #26 
 
Total literature from search: 492   
Embase #1: Exp schizophrenia 
#2: Metabolic syndrome 
#3: Chronic obstructive lung disease 
#4: Exp diabetes mellitus 
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#5: Exp diabetic angiopathy 
#6: Exp experimental diabetes mellitus  
#7: Exp pregnancy diabetes mellitus 
#8: #4 OR #5 OR #6 OR #7 
 
#9: Exp cardiovascular disease  
#10: Exp comorbidity 
#11: #2 OR #3 OR #8 OR #9 OR #10 
#12: #1 AND #11 
 
#13: Exp medical error 
#14: Outcome assessment 
#15: Health care disparity 
#16: Disparit* 
#17: Inequalit* 
#18: Inadequacy 
#19: Diagnostic error* 
#20: Underdetect*  
#21: Misclassif* 
#22: Misinterpret* 
#23: #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 (ti,ab,kw) 
#24: #13 OR #14 OR #15 OR #23 
#25: #12 AND #24 
 
Total literature from search: 536 
PsycINFO #1: Exp schizophrenia 
#2: Schizophren*.ti,ab 
#3: #1 OR #2 
 
#4: Metabolic syndrome 
#5: Metabolic syndrome*.ti,ab 
#6: Cardiovascular disease*.ti,ab 
#7: Diabetes Mellitus 
#8: Diabet*.ti,ab 
#9: Exp chronic obstructive pulmonary disease 
#10: Copd 
#11: Chronic obstructive pulmonary disease* 
#12: #10 OR #11 (ti,ab) 
 
#13: Exp cardiovascular disorders 
#14: Exp comorbidity 
#15:Comorbidit*ti,ab 
#16: #14 OR #15 
#17: #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #12 OR #13 OR #16 
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#18: #3 AND #17 
 
#19: Exp treatment outcomes 
#20: Health disparities 
#21: Disparit* 
#22: Inequalit* 
#23: Inadequacy 
#24: Diagnostic error* 
#25: Undertetect* 
#26: Misclassif* 
#27: Misinterpret*  
#28: Medical error* 
#29: #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 
(ti,ab) 
#30: #19 OR #20 OR #29 
#31: #18 AND #30 
 
Total literature from search: 97 
Cinahl #1: MH “schizophrenia” 
#2: Schizophren* 
#3: #1 OR #2 
 
#4: MH ”metabolic syndrome X” 
#5: Metabolic syndrome* 
#6: MH ”cardiovascular diseases+” 
#7: Cardiovascular disease* 
#8: MH ”Diabetes Mellitus+” 
#9: Diabet* 
#10: MH “pulmonary disease, chronic obstructive+” 
#11: Copd 
#12: Chronic obstructive pulmonary disease* 
#13: #11 OR #12 
 
#14: MH “Comorbidity” 
#15: #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #13 OR #14 
#16: #3 AND #15 
 
#17: MH “health care errors+” 
#18: MH “outcome assessment” 
#19: MH “healthcare disparities” 
#20: Disparit* 
#21: Inequalit* 
#22: Inadequacy 
#23: Diagnostic error* 
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#24: Undertetect* 
#25: Misclassif* 
#26: Misinterpret*  
#27: #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 
OR #25 OR #26 
#28: #16 AND #27 
 
Total literature from search: 28 
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Appendix B. Flow diagram of the 
literature identification 
Figure A1 A flow diagram of the identified papers from the literature search 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Additional literature identified 
through other sources (N=12) 
Literature identified through 
database searching (N=1,153) 
Papers after duplicates removed 
(N=1,070) 
Papers screened  
(N=1,070) 
Full-text papers assessed for 
eligibility (N=52) 
Papers included  
(N=18) 
Papers excluded 
(non-relevant 
title, abstract or 
full text) 
(N=1,018) 
Full-text papers 
excluded (non-
comparative 
results, weak or 
unclear design, 
small study 
populations) 
(N=34) 
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Appendix C. Study I 
 
Quality and predictors of diabetes care among patients with schizophrenia: a 
nationwide study 
Jørgensen M, Mainz J, Carinci F, Thomsen RW, Johnsen SP 
In review
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Appendix D. Study II 
 
Quality of care and clinical outcomes of heart failure among patients with 
schizophrenia under universal health care  
Jørgensen M, Mainz J, Egstrup K, Johnsen SP 
In preparation 
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Appendix E. Study III 
 
Chronic obstructive pulmonary disease care and outcomes in patients with 
schizophrenia 
Jørgensen M, Mainz J, Lange P, Johnsen SP 
Submitted
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